

1 Michael L. Baum, Esq. (SBN 119511)

2 [mbaum@baumhedlundlaw.com](mailto:mbaum@baumhedlundlaw.com)

3 Bijan Esfandiari, Esq. (SBN 223216)

4 [besfandiari@baumhedlundlaw.com](mailto:besfandiari@baumhedlundlaw.com)

5 Stephanie Sherman, Esq. (SBN 338390)

6 [ssherman@baumhedlundlaw.com](mailto:ssherman@baumhedlundlaw.com)

7 Monique Alarcon, Esq. (SBN 311650)

8 [malarcon@baumhedlundlaw.com](mailto:malarcon@baumhedlundlaw.com)

9 Harrison E. James, Esq. (SBN 337733)

10 [hjames@baumhedlundlaw.com](mailto:hjames@baumhedlundlaw.com)

11 **BAUM, HEDLUND, ARISTEI, & GOLDMAN, P.C.**

12 10940 Wilshire Blvd., Suite 1600

13 Los Angeles, CA 90024

14 Telephone: (310) 207-3233

15 Facsimile: (310) 820-7444

16 *Attorneys for Plaintiff*

17 **IN THE UNITED STATES DISTRICT COURT**  
18 **FOR THE CENTRAL DISTRICT OF CALIFORNIA**

19 CATHERINE BOSS,

20 Plaintiff,

21 v.

22 MERCK & CO., INC., a New Jersey  
23 Corporation; and MERCK SHARP &  
24 DOHME CORP., a New Jersey Corporation,

25 Defendants.

Case No.

**COMPLAINT FOR**

- (1) Negligence
- (2) Strict Liability (Failure to Warn)
- (3) Strict Liability (Manufacturing Defect)
- (4) Breach of Warranty
- (5) Common Law Fraud
- (6) Violation of California's Unfair Competition Law

**DEMAND FOR JURY TRIAL**

**TABLE OF CONTENTS**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

Page

INTRODUCTION ..... 6

PARTIES AND VENUE ..... 6

GENERAL ALLEGATIONS ..... 8

I. “History Doesn’t Repeat Itself, But It Often Rhymes” – Mark Twain..... 8

II. In Bringing Its Holy Grail, Gardasil, to Market, Merck Engaged in the Same Fraudulent Research and Marketing It Had Engaged in Vis-à-vis Vioxx Resulting In Patients Being Exposed to a Vaccine That is Of Questionable Efficacy and Which Can Cause Serious and Debilitating Adverse Events..... 11

A. Overview of the Human Papillomavirus..... 12

B. Overview of the Gardasil Vaccine and Its Fast-Tracked Approval..... 14

C. Merck Engaged in Disease Mongering and False Advertising to Enhance Gardasil Sales ..... 18

D. Merck Used Scare Tactics and Provided Financial Incentives to Legislatures to Attempt to make the Gardasil Vaccine Mandatory for All School Children..... 21

E. Merck Pushed Gardasil Using Trusted Doctors and Third-Party Front Groups ..... 23

F. Merck Has Systematically Misrepresented the Efficacy of Gardasil By Advertising that Gardasil Prevents Cervical Cancer When There Are No Clinical Studies to Support This False Claim ..... 24

G. The Gardasil Vaccines Contain Numerous Hazardous Ingredients, Including At Least One Ingredient Merck Failed to Disclose to Regulators and the Public..... 27

i. Gardasil Contains A Toxic Aluminum Adjuvant ..... 27

ii. Merck Lied About a Secret DNA Adjuvant Contained in The Gardasil Vaccines ..... 28

1           iii.    Gardasil Contains Borax .....29

2           iv.    Gardasil Contains Polysorbate 80..... 30

3           v.    Gardasil Contains Genetically Modified Yeast ..... 30

4           H.    As it Did in Vioxx, In Orchestrating and Conducting Its Clinical

5                Trials for Gardasil, Merck Concealed Risks to Falsely Enhance the

6                Safety Profile of Gardasil..... 31

7                i.    Small Clinical Trials ..... 33

8                ii.   Merck Used a Highly Toxic “Placebo” to Mask Gardasil

9                Injuries ..... 33

10              iii.   Merck Used Exclusionary Criteria to Further Conceal Gardasil

11              Risks..... 35

12              iv.   Merck Deceived Regulators and The Public by Classifying

13              Many Serious Adverse Events, Which Afflicted Nearly Half

14              of All Study Participants, As Coincidences..... 36

15              v.    Merck Manipulated the Study Protocols to Block Participants

16              and Researchers from Reporting Injuries and Devised the

17              Studies to Mask Any Long-Term Adverse Events ..... 37

18              vi.   Merck Deceived Regulators and the Public About Its Pivotal

19              Gardasil Clinical Trial (Protocol 018) ..... 39

20           I.    Contrary to Merck’s Representations, Gardasil May Actually Cause

21                and Increase the Risk of Cervical and Other Cancers..... 42

22           J.    Merck has Concealed the Fact that Gardasil Induces and Increases

23                the Risk of Autoimmune Diseases, and Other Injuries, Including But

24                Not Limited to, Postural Orthostatic Tachycardia Syndrome, Chronic

25                Fatigue Syndrome, Neuropathy, Fibromyalgia and Dysautonomia ..... 44

26           K.    Merck has Concealed the Fact that Gardasil Increases the Risk of

27                Fertility Problems ..... 51

28           L.    There were an Increased Number of Deaths in the Gardasil Studies ..... 52

              M.    Post-Marketing Injuries -- The Raft of Injuries Seen in Merck’s

                  Clinical Trials Has Now Become A Population-Wide Chronic

                  Disease Epidemic ..... 53

1 N. The Gardasil Vaccines’ Harms Are Not Limited to the United States,  
 2 Rather the Vaccines Have Injured Patients All Over the World ..... 55  
 3 i. In Light of Gardasil’s Serious and Debilitating Adverse Events,  
 4 the Japanese Government Rescinded Its Recommendation that  
 5 Girls Receive Gardasil ..... 55  
 6 ii. Denmark Has Opened Specialized Clinics Specifically Focused  
 7 on Treating Gardasil-Induced Injuries, Including Gardasil-  
 8 Induced Autoimmune Diseases ..... 56  
 9 iii. Gardasil-Induced Adverse Events Caused the Government in  
 10 Colombia to Conclude that Gardasil Would No Longer Be  
 11 Mandatory ..... 57  
 12 iv. India Halted Gardasil Trials and Accused Merck of Corruption  
 13 After the Death of Several Young Girls Who were Participants  
 14 in the Trial..... 57  
 15 O. Merck’s Fraud Has Paid Off Handsomely Resulting in Over \$3 Billion  
 16 in Gardasil Sales Annually..... 59  
 17 III. Catherine Boss Sustained Autoimmune Disease, Postural Orthostatic  
 18 Tachycardia Syndrome, Dysautonomia, and Other Serious Injuries, as A  
 19 Result of Her Gardasil Injection(s) ..... 60  
 20 A. Gardasil and Its Ingredients Caused Plaintiff’s Autoimmune Disease  
 21 and Other Related Injuries and Has Resulted in Her Suffering from  
 22 Severe, Debilitating, Disabling and Painful Chronic Injuries..... 60  
 23 B. “It is Not Revolutions and Upheavals That Clear the Road to New and  
 24 Better Days, But Revelations, Lavishness and Torments of Someone’s  
 25 Soul, Inspired and Ablaze.” – Boris Pasternak, After the Storm..... 63  
 26 CAUSES OF ACTION ..... 64  
 27 COUNT ONE NEGLIGENCE ..... 64  
 28 COUNT TWO STRICT LIABILITY (FAILURE TO WARN)..... 72  
 COUNT THREE STRICT LIABILITY (MANUFACTURING DEFECT) ..... 76  
 COUNT FOUR BREACH OF EXPRESS WARRANTY ..... 79  
 COUNT FIVE COMMON LAW FRAUD ..... 82

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

COUNT SIX VIOLATION OF CALIFORNIA’S UNFAIR  
COMPETITION LAW..... 89

PRAYER FOR RELIEF ..... 92

DEMAND FOR JURY TRIAL ..... 93

1 COMES NOW Plaintiff, CATHERINE BOSS, who by and through counsel  
2 Baum Hedlund Aristei & Goldman, PC and Robert F. Kennedy, Jr., and alleges against  
3 defendants MERCK & CO., INC., and MERCK, SHARP AND DOHME  
4 CORPORATION, and each of them, as follows:

5 **INTRODUCTION**

6 1. This common-law products liability, negligence, strict liability, breach of  
7 warranty and fraud action arises out of serious and debilitating injuries, including but  
8 not limited to autonomic, neurological and heterogenous autoimmune injuries and  
9 resulting sequelae that plaintiff, Catherine Boss (“Plaintiff”), sustained as a result of  
10 receiving the Gardasil vaccine, which was manufactured, labeled, and promoted by  
11 defendants Merck & Co., Inc., and Merck, Sharp and Dohme Corporation (collectively  
12 “Merck”).

13 **PARTIES AND VENUE**

14 2. Plaintiff, Catherine Boss (“Boss” or “Plaintiff”), is an adult and a resident  
15 and citizen of California.

16 3. Defendant Merck & Co., Inc., is a New Jersey corporation with its  
17 principal place of business at One Merck Drive, Whitehouse Station, New Jersey.

18 4. Defendant Merck, Sharp and Dohme Corporation, is a New Jersey  
19 corporation with its principal place of business at One Merck Drive, Whitehouse  
20 Station, New Jersey.

21 5. Defendants Merck & Co., Inc., and Merck, Sharp and Dohme Corporation  
22 shall hereinafter collectively be referred to as “Merck.”

23 6. At all times herein mentioned, each defendant was the agent, servant,  
24 partner, aider and abettor, co-conspirator and/or joint venturer of the other defendants  
25 named herein and was at all times operating and acting within the purpose and scope of  
26 said agency, service, employment, partnership, conspiracy and/or joint venture and  
27 rendered substantial assistance and encouragement to the other defendants, knowing  
28 that their collective conduct constituted a breach of duty owed to Plaintiff.

1           7.     At all times herein mentioned, defendants were fully informed of the  
2 actions of their agents and employees, and thereafter no officer, director or managing  
3 agent of defendants repudiated those actions, which failure to repudiate constituted  
4 adoption and approval of said actions and all defendants and each of them, thereby  
5 ratified those actions.

6           8.     There exists and, at all times herein mentioned there existed, a unity of  
7 interest in  
8 ownership between the named defendants, such that any individuality and separateness  
9 between the defendants has ceased and these defendants are the alter-ego of each other  
10 and exerted control over each other. Adherence to the fiction of the separate existence  
11 of these two named defendants as entities distinct from each other will permit an abuse  
12 of the corporate privilege and would sanction a fraud and/or would promote injustice.

13           9.     At all times herein mentioned, the two Merck defendants were engaged in  
14 the business of, or were successors in interest to, entities engaged in the business of  
15 researching, formulating, compounding, testing, manufacturing, producing, processing,  
16 assembling, inspecting, distributing, marketing, labeling, promoting, packaging,  
17 prescribing and/or advertising for sale, and selling products for use by patients such as  
18 Plaintiff and her medical providers. As such, the two Merck defendants are each  
19 individually, as well as jointly and severally, liable to Plaintiff for her damages.

20           10.    The harm caused to Plaintiff resulted from the conduct of one or various  
21 combinations of the two Merck defendants, and through no fault of Plaintiff. There  
22 may be uncertainty as to which one or which combination of the two Merck defendants  
23 caused the harm. The two Merck defendants have superior knowledge and information  
24 on the subject of which one or which combination of the two defendants caused  
25 Plaintiff's injuries. Thus, the burden of proof should be upon each of the two Merck  
26 defendants to prove that the defendant has not caused the harms Plaintiff has suffered.  
27 As previously stated, the two named Merck defendants shall hereinafter and throughout  
28 this Complaint be collectively referred to as "Merck."

1 11. Merck is the manufacturer, labeler and promoter of the Gardasil and  
2 Gardasil-9 vaccines, which are purported to be “cervical cancer vaccines” and “anal  
3 cancer vaccines” by preventing a handful of the hundreds of strains of the Human  
4 Papillomavirus (“HPV”). Merck regularly conducts and transacts business in  
5 California and has promoted Gardasil to consumers, patients, hospitals, physicians,  
6 nurses and medical professionals, including but not limited to Plaintiff, and the medical  
7 facility and medical professionals who prescribed and/or injected Plaintiff with  
8 Gardasil. This Court has personal jurisdiction over Merck because defendants have  
9 sufficient minimum contacts with California to render the exercise of jurisdiction by  
10 this Court proper.

11 12. This Court has subject matter jurisdiction over the parties pursuant to 28  
12 U.S.C. §1332(a) because Plaintiff and the defendants are citizens of different states and  
13 the amount of controversy exceeds \$75,000.00, exclusive of interest and costs.

14 13. Venue is proper in this Court pursuant to 28 U.S.C. §1391 because a  
15 substantial portion of the events and omissions giving rise to the claims asserted herein  
16 occurred in this District.

### 17 **GENERAL ALLEGATIONS**

#### 18 **I. “History Doesn’t Repeat Itself, But It Often Rhymes” – Mark Twain**

19 14. Merck traces its history back to 1668, when the original founder of the  
20 company, Friedrich Jacob Merck, bought an apothecary in Darmstadt, Germany. The  
21 company operated as a pharmacy for approximately the next 150+ years when, in 1827,  
22 Friedrich’s descendant, Heinrich Emmanuel Merck, converted the company into a drug  
23 manufacturing enterprise. Merck’s first products included morphine and cocaine.

24 15. Merck later manufactured a number of controversial products including  
25 Fosamax (a purported bone density drug that caused bone fractures), Nuvaring (a birth  
26 control device associated with life-threatening blood clots and death), and probably its  
27 most infamous drug, Vioxx (a pain medication Merck was forced to pull from the  
28 market due to its cardiovascular risks), all of which landed Merck in litigation hot

1 water.

2 16. With regard to Vioxx, Merck was sued by tens of thousands of patients  
3 who alleged they suffered heart attacks and other cardiovascular injuries as a result of  
4 ingesting the blockbuster pain medication.

5 17. Documents unsealed during the Vioxx litigation in the early 2000s revealed  
6 a culture wherein Merck knew early on that Vioxx was linked to fatal cardiovascular  
7 adverse events but nonetheless intentionally chose to conceal these risks from the  
8 public and medical community and, instead, orchestrated a scheme to downplay the  
9 severity of the risks. Merck misrepresented the results of its clinical trials, failed to  
10 undertake the clinical trials that would reveal risks, and blacklisted medical  
11 professionals who dared to publicly criticize the safety of Vioxx. *See e.g.*, Eric J.  
12 Topol, *Failing the Public Health – Rofecoxib, Merck, and the FDA*, 351 NEW ENGLAND  
13 JOURNAL OF MEDICINE 1707 (2004); Gregory D. Curfman et al., *Expression of Concern*  
14 *Reaffirmed*, 354 NEW ENGLAND JOURNAL OF MEDICINE 1193 (2006); Aaron S.  
15 Kesselheim et al., *Role of Litigation in Defining Drug Risks*, 17 JAMA 308 (2007);  
16 Harlan M. Krumholz et al., *What We Have Learnt From Vioxx*, 334 BRITISH MED. J.  
17 120 (2007).

18 18. The British Medical Journal reported that internal documents and  
19 communications obtained from Merck during litigation revealed that Merck scientists  
20 internally acknowledged the existence of Vioxx’s risks very early on: “Since the early  
21 development of [Vioxx], some scientists at Merck were concerned that the drug might  
22 adversely affect the cardiovascular system ... In internal emails made public through  
23 litigation, Merck officials sought to soften the academic authors’ interpretation [of the  
24 data]. The academic authors changed the manuscript at Merck’s request [to make less  
25 of the apparent risk] ...” Harlan M. Krumholz et al., *What We Have Learnt From*  
26 *Vioxx*, 334 BRITISH MED. J. 120 (2007). And, despite Merck’s knowledge of the risk,  
27 Merck never conducted the necessary studies designed to evaluate cardiovascular risk.  
28 *Id.*

1           19. In an article published in the Journal of the American Medical Association,  
2 it was reported that Merck worked to “diminish the impact of reported cardiovascular  
3 adverse effects by not publishing adverse events and failing to include complete data on  
4 myocardial infarctions that occurred during a key clinical trial. The information came  
5 to the public attention through a subpoena 5 years after the article’s publication, when  
6 [Vioxx] was already off the market.” Aaron S. Kesselheim et al., *Role of Litigation in*  
7 *Defining Drug Risks*, 17 JAMA 308 (2007). The article concludes: “These case studies  
8 indicate that clinical trials and routine regulatory oversight as currently practiced often  
9 fail to uncover important adverse effects for widely marketed products. In each  
10 instance, the litigation process revealed new data on the incidence of adverse events,  
11 enabled reassessment of drug risks through better evaluation of data, and influenced  
12 corporate and regulatory behavior.” *Id.*

13           20. It was also revealed and reported that, in order to control the public  
14 narrative that Vioxx was safe and risk free, “Merck issued a relentless series of  
15 publications...complemented by numerous papers in peer-reviewed medical literature  
16 by Merck employees and their consultants. The company sponsored countless  
17 continuing medical ‘education’ symposiums at national meetings in an effort to debunk  
18 the concern about adverse cardiovascular effects.” Eric J. Topol, *Failing the Public*  
19 *Health – Rofecoxib, Merck, and the FDA*, 351 NEW ENGLAND JOURNAL OF MEDICINE  
20 1707 (2004). In addition, Merck “selectively targeted doctors who raised questions  
21 about [Vioxx], going so far as pressuring some of them through department chairs.”  
22 Harlan M. Krumholz et al., *What We Have Learnt From Vioxx*, 334 BRITISH MED. J.  
23 120 (2007). Dr. Topol, Chairman of the Department of Cardiovascular Medicine at the  
24 Cleveland Clinic, commented: “Sadly, it is clear to me that Merck’s commercial  
25 interest in [Vioxx] sales exceeded its concern about the drug’s potential cardiovascular  
26 toxicity.” Eric J. Topol, *Failing the Public Health – Rofecoxib, Merck, and the FDA*,  
27 351 NEW ENGLAND JOURNAL OF MEDICINE 1707 (2004).

28           21. Once Merck’s misdeeds vis-à-vis Vioxx were revealed in various jury

1 trials, Merck paid nearly \$5 billion to settle the tens of thousands of personal injury  
2 actions that had been brought against it as a result of its concealment of Vioxx’s  
3 cardiovascular risks. Merck paid an additional \$1 billion to settle a securities class  
4 action brought by investors who had lost money when Merck’s stock tanked following  
5 revelations of the drug’s risks and subsequent lost sales. Merck was also forced to pay  
6 \$950 million in civil and criminal fines to the Department of Justice and other  
7 governmental entities as a result of various criminal activities Merck had engaged in  
8 with respect to Vioxx.

9 22. In 2005, Merck pulled Vioxx from the market and was desperate to find a  
10 replacement for its previous multi-billion-dollar blockbuster.

11 23. Gardasil was viewed as the answer to the financial woes Merck had  
12 suffered from Vioxx.

13 24. Indeed, some have euphemistically noted that HPV stood for “Help Pay for  
14 Vioxx.”

15 25. In the aftermath of the Vioxx scandal, and seeking a replacement product,  
16 Merck’s senior director of clinical research, Eliav Barr, M.D., proclaimed of Gardasil:  
17 “This is it. *This is the Holy Grail!*”

18 **II. In Bringing Its Holy Grail, Gardasil, to Market, Merck Engaged in the Same**  
19 **Fraudulent Research and Marketing It Had Engaged in Vis-à-vis Vioxx**  
20 **Resulting In Patients Being Exposed to a Vaccine That is Of Questionable**  
21 **Efficacy and Which Can Cause Serious and Debilitating Adverse Events**

22 26. As outlined herein, in researching, developing, and marketing its new Holy  
23 Grail, Gardasil, Merck engaged in the same unscrupulous tactics it had so infamously  
24 engaged in with  
25 Vioxx.

26 27. Certain Merck employees, scientists and executives involved in the Vioxx  
27 scandal were  
28 also involved with Gardasil, and it appears they employed the very same methods of  
manipulating

1 science and obscuring risks as they did with Vioxx.

2 28. According to Merck’s marketing claims, Gardasil (and, later, next-  
3 generation Gardasil 9) provided lifetime immunity to cervical, anal and other HPV-  
4 associated cancers.

5 29. As discussed more fully below, whether Gardasil prevents cancer (not to  
6 mention lifetime immunity), is unproven. In fact, it may be more likely to cause cancer  
7 in those previously exposed to HPV than to prevent it.

8 30. Moreover, Merck knows and actively conceals the fact that Gardasil can  
9 cause a constellation of serious adverse reactions and gruesome diseases, including  
10 autoimmune diseases, and death in some recipients.

11 31. As a result of Merck’s fraud, Gardasil today is wreaking havoc on a  
12 substantial swath of an entire generation of children and young adults on a worldwide  
13 scale.

#### 14 **A. Overview of the Human Papillomavirus**

15 32. Human Papillomavirus (“HPV”) is a viral infection that is passed between  
16 people through skin-to-skin contact. There are more than 200 strains of HPV, and of  
17 those, more than 40 strains can be passed through sexual contact.

18 33. HPV is the most common sexually transmitted disease. It is so common  
19 that the majority of sexually active people will get it at some point in their lives, even if  
20 they have few sexual partners.

21 34. HPV, for the most part, is benign. More than 90 percent of HPV infections  
22 cause no clinical symptoms, are self-limited, and are removed from the human body by  
23 its own immunological mechanisms and disappear naturally from the body following  
24 an infection. *See, e.g., Antonio C. de Freitas et al., Susceptibility to cervical cancer: An*  
25 *Overview*, 126 GYNECOLOGIC ONCOLOGY 306 (August 2012).

26 35. Approximately 12 to 18 of the over 200 strains of HPV are believed to be  
27 associated with cervical cancer, and approximately six of the strains are believed to be  
28 associated with anal

1 cancer.

2 36. Not every HPV infection puts one at risk for cervical cancer. Only  
3 persistent HPV infections – not short-term or transient infections or sequential  
4 infections with different HPV types – in a limited number of cases with certain strains  
5 of the virus may cause the development of precancerous lesions. With respect to  
6 cervical cancer, these precancerous lesions are typically diagnosed through Pap smears  
7 and then removed through medical procedures. However, when undiagnosed, they may  
8 in some cases progress to cervical cancer in some women. Other risk factors, such as  
9 smoking, are also associated with cervical cancer. *See* Antonio C. de Freitas et al.,  
10 *Susceptibility to cervical cancer: An Overview*, 126 GYNECOLOGIC ONCOLOGY 305  
11 (August 2012). Infection with certain types of HPV are also associated with other  
12 diseases, such as genital warts.

13 37. Public health officials have long recommended the Pap test (also known as  
14 Pap Smear), which detects abnormalities in cervical tissue, as the most effective  
15 frontline public health response to the disease.

16 38. Since its introduction, cervical cancer screening through the Pap test has  
17 reduced the rates of cervical cancer in developed countries by up to 80 percent. *Id.*

18 39. Incidences of cervical cancer have been declining dramatically worldwide  
19 as countries have implemented Pap screening programs.

20 40. New cases of cervical cancer in the U.S. affect approximately 0.8 percent  
21 of women in their lifetime. *See Cancer Stat Facts: Cervical Cancer*, NIH, at  
22 <https://seer.cancer.gov/statfacts/html/cervix.html>. For those who are diagnosed,  
23 cervical cancer is largely treatable, with a five-year survival rate of over 90 percent  
24 when the cancer is caught early. *See* Antonio C. de Freitas et al., *Susceptibility to*  
25 *cervical cancer: An Overview*, 126 GYNECOLOGIC ONCOLOGY 305 (August 2012). Anal  
26 cancer is even more rare, and according to the current data, approximately 0.2 percent  
27 of people will be diagnosed with anal cancer in their lifetime.

28 41. Although the incidence of cervical cancer was in rapid decline as a result of

1 the implementation of routine testing and screening, including the Pap test and various  
2 DNA testing measures, Merck sought to fast-track a vaccine onto the market to prevent  
3 infection from four types of HPV (only two of which are associated with cancer).

4 **B. Overview of the Gardasil Vaccine and Its Fast-Tracked Approval**

5 42. While there are over 200 types of the HPV virus, only 12 to 18 types  
6 currently are considered potentially associated with cervical or anal cancer. Merck's  
7 original Gardasil vaccine claimed to prevent infections from four strains (HPV Strain  
8 Types 6, 11, 16 and 18) and only two of those (Types 16 and 18) were associated with  
9 cervical and anal cancer.

10 43. Under Food and Drug Administration ("FDA") requirements, to obtain  
11 approval for  
12 marketing a vaccine, the manufacturer must conduct studies to test the effectiveness  
13 and safety of the vaccine. Once FDA approval is obtained, the manufacturer has a duty  
14 to perform any further scientific and medical investigation as a reasonably prudent  
15 manufacturer would perform, and to engage in any necessary post-marketing  
16 pharmacovigilance related to the product.

17 44. The FDA approved Gardasil on June 8, 2006, after granting Merck fast-  
18 track status and speeding the approval process to a six-month period, leaving  
19 unanswered material questions relating to its effectiveness and safety as well as when  
20 and to whom the Gardasil vaccine ought to be administered.

21 45. Merck failed, during the preapproval processing period and thereafter, to  
22 disclose (to the FDA and/or the public), material facts and information relating to the  
23 effectiveness and safety of Gardasil, as well as to whom the vaccine should or should  
24 not be administered.

25 46. Merck failed to perform in the preapproval processing period and  
26 thereafter, scientific and medical investigations and studies relating to the safety,  
27 effectiveness and need for the Gardasil vaccine as either required by and under FDA  
28 directives and regulations, and/or those which a prudent manufacturer should have

1 conducted unilaterally.

2 47. In June 2006, after the FDA's fast-tracked review, Gardasil was approved  
3 for use in females ages nine through 26 for the purported prevention of cervical cancer  
4 and, almost immediately thereafter, the Advisory Committee on Immunization  
5 Practices ("ACIP"), a committee within the Centers for Disease Control ("CDC"),  
6 recommended Gardasil for routine vaccination of adolescent girls ages eleven and  
7 twelve years old, but also allowed it to be administered to girls as young as nine years  
8 old.

9 48. On October 16, 2009, the FDA approved Gardasil for use in boys ages nine  
10 through 26 for the prevention of genital warts caused by HPV types 6 and 11, and in  
11 December 2010, it approved Gardasil for the purported prevention of anal cancer in  
12 males and females ages nine through 26.

13 49. Subsequently, Merck sought approval for Gardasil 9 (containing the same  
14 ingredients as Gardasil, but in higher quantities), which purportedly guarded against  
15 five additional HPV strains currently associated with cervical cancer and anal cancer  
16 (HPV Types 31, 33, 45, 52 and 58) than the original Gardasil, for a total of nine strains.

17 50. The FDA approved Gardasil 9 in December 2014, for use in girls ages nine  
18 through 26 and boys ages nine through 15 for the purported prevention of cervical,  
19 vaginal, and anal cancers. Presently, Gardasil 9 has been approved for and is being  
20 promoted by Merck to males and females who are between nine and 45 years of age,  
21 with an emphasis by Merck on marketing to pre-teen children and their parents. With  
22 little evidence of efficacy, the FDA also recently approved, on an accelerated basis,  
23 Gardasil 9 for prevention of oropharyngeal and other head and neck cancers.

24 51. After the approval of the Gardasil 9 vaccine, the original Gardasil vaccine  
25 was phased out of the U.S. Market; and the original Gardasil vaccine is no longer  
26 available for sale in the United States.

27 52. According to data from the National Cancer Institute's ("NCI")  
28 Surveillance, Epidemiology and End Results Program ("SEER"), the incidence of

1 deaths from cervical cancer prior to Gardasil’s introduction in the United States had  
2 been steadily declining for years and, in 2006, was 2.4 per 100,000 women or  
3 approximately 1 in every 42,000 women. The currently available rate is essentially  
4 unchanged, 2.2 per 100,000 women, based on data through 2017.

5 53. The median age of death from cervical cancer is 58, and death from anal  
6 cancer is 66, and teenagers (who are the target population of Gardasil) essentially have  
7 zero risk of dying from cervical or anal cancer.

8 54. Merck purchased fast-track review for Gardasil and Gardasil 9 under the  
9 Prescription Drug User Fee Act (“PDUFA”). Fast-track is a process designed to  
10 facilitate the development of drugs, and to expedite their review, in order to treat  
11 serious conditions and fill an unmet medical need.

12 55. Anxious to get Gardasil onto the market as soon as possible following the  
13 Vioxx debacle, Merck sought fast-track approval even though there already existed a  
14 highly effective and side-effect free intervention, Pap smears, with no evidence that  
15 Gardasil was potentially superior to Pap smears in preventing cervical cancer.

16 56. In fact, the clinical trials Merck undertook did not even examine Gardasil’s  
17 potential to prevent cancer, rather, the trials only analyzed whether Gardasil could  
18 prevent potential precursor conditions, i.e., HPV infections and cervical interepithelial  
19 neoplasia (“CIN”) lesions graded from CIN1 (least serious) to CIN3 (most serious), the  
20 vast majority of which resolve on their own without intervention. CIN2 and CIN3 were  
21 the primary surrogate endpoints studied. Likewise, the clinical trials from Gardasil did  
22 not examine Gardasil’s potential to prevent anal cancer, rather, the trials similarly only  
23 look at anal intraepithelial neoplasia (“AIN”) lesions graded 1 through 3, and the  
24 Gardasil 9 studies did not even include any studies concerning the efficacy of Gardasil  
25 in preventing anal lesions.

26 57. According to the FDA, whether a condition is “serious” depends on such  
27 factors as “survival, day-to-day functioning, or the likelihood that the condition, if left  
28 untreated, will progress from a less severe condition to a more serious one.”

1 58. As previously discussed, over 90 percent of HPV infections and the  
2 majority of cervical dysplasia, resolve without intervention.

3 59. However, Merck presented misleading data to the FDA suggesting that  
4 CIN2 and CIN3 inexorably result in cancer.

5 60. Federal law allows fast-track approval when there is no existing  
6 intervention to treat the targeted disease or where the proposed treatment is potentially  
7 superior to an existing treatment.

8 61. Merck knows (and knew) that Gardasil and Gardasil 9 are far less effective  
9 than Pap tests in preventing cervical cancer.

10 62. In order to obtain FDA approval, Merck devised and conducted a series of  
11 fraudulent Gardasil studies and then influenced the votes of the FDA's Vaccines and  
12 Related Biological Products Advisory Committee ("VRBPAC") and the CDC's  
13 Advisory Committee on Immunization Practices ("ACIP") to win both an FDA license  
14 and a CDC/ACIP approval and recommendation that all 11 and 12 year old girls should  
15 be vaccinated with Gardasil.

16 63. That ACIP "recommendation" was, effectively, a mandate to doctors to sell  
17 Merck's very expensive vaccine, thereby compelling parents of American children as  
18 young as nine years old to buy this expensive product. With ACIP's recommendation,  
19 Merck was emboldened to build demand through direct-to-consumer advertising and  
20 door-to-door marketing to doctors, and, with the ACIP's blessing of the vaccine,  
21 circumvented the need to create a traditional market for the product.

22 64. Julie Gerberding, then the Director of CDC, obligingly ushered the  
23 Gardasil vaccine through CDC's regulatory process manifestly ignoring clear evidence  
24 that Gardasil's efficacy was unproven and that the vaccine was potentially dangerous.

25 65. Merck, shortly thereafter, rewarded Gerberding by naming her President of  
26 Merck Vaccines in 2010.

27 66. In addition to the revolving regulatory/industry door, (wherein the Director  
28 of CDC who approved the vaccine is subsequently employed by the manufacturer as a

1 high-level executive to oversee the commercial success of the vaccine she previously  
2 approved), it is also worth noting some of the other conflicts of interest that exist within  
3 governmental agencies in relation to the facts surrounding Gardasil. Scientists from the  
4 National Institute of Health (“NIH”), which is a division of the United States  
5 Department of Health and Human Services (“HHS”), discovered a method of producing  
6 “virus-like-particles” (“VLPs”) that made creation of the Gardasil vaccine possible.  
7 The NIH scientists’ method of producing VLPs was patented by the Office of  
8 Technology Transfer (“OTT”), which is part of the NIH, and the licensing rights were  
9 sold to Merck (for manufacture of Gardasil). Not only does the NIH (and, in effect, the  
10 HHS) receive royalties from sales of Gardasil, but the scientists whose names appear on  
11 the vaccine patents can receive up to \$150,000 per year (in perpetuity). Accordingly,  
12 the Gardasil patents have earned HHS, NIH and the scientists who invented the  
13 technology millions of dollars in revenue.

14 67. Moreover, members of ACIP have been allowed to vote on vaccine  
15 recommendations even if they have financial ties to drug companies developing similar  
16 vaccines. According to a 2000 U.S. House of Representatives investigation report, the  
17 majority of the CDC’s eight ACIP committee members had conflicts of interest. The  
18 Chairman of ACIP served on Merck’s Immunization Advisory Board and a number of  
19 the other ACIP members had received grants, salaries, or other forms of remuneration  
20 from Merck

21 **C. Merck Engaged in Disease Mongering and False Advertising to**  
22 **Enhance Gardasil Sales**

23 68. Both prior to and after the approval of Gardasil, Merck engaged in  
24 unscrupulous marketing tactics designed to overemphasize both the risks associated  
25 with HPV and the purported efficacy of Gardasil to scare the public into agreeing to  
26 mass vaccinations of the Gardasil vaccine.

27 69. Prior to Merck’s aggressive marketing campaign, there was no HPV public  
28 health emergency in high-resource countries, such as the United States.

1           70. Most women had never heard of HPV. The NCI’s 2005 Health  
2 Information National Trends Survey (“HINTS”) found that, among U.S. women 18 to  
3 75 years old, only 40 percent had heard of HPV. Among those who had heard of HPV,  
4 less than half knew of an association between HPV and cervical cancer. Furthermore,  
5 only four percent knew that the vast majority of HPV infections resolve without  
6 treatment.

7           71. The stage was set for Merck to “educate” the public about HPV, cervical  
8 cancer, and Gardasil, all to Merck’s advantage.

9           72. Merck preceded its rollout of Gardasil with years of expensive disease  
10 awareness marketing. Merck ran “Tell Someone” commercials, designed to strike fear  
11 in people about HPV and cervical cancer – even ominously warning that you could  
12 have HPV and not know it. The commercials could not mention Gardasil, which had  
13 not yet been approved by FDA, but did include Merck’s logo and name. Critics of  
14 Merck’s pre-approval advertising and promotion called it “deceptive and dishonest.”  
15 While Merck claims the promotion was part of public health education, critics  
16 complained that this “education” was designed to sell Gardasil and build the market for  
17 the vaccine. *See* Angela Zimm and Justin Blum, *Merck Promotes Cervical Cancer*  
18 *Shot by Publicizing Viral Cause*, BLOOMBERG NEWS, May 26, 2006.

19           73. A year before obtaining licensing for its vaccine, Merck engaged in a major  
20 offensive in “disease branding” to create a market for its vaccine out of thin air. *See*  
21 Beth Herskovits, *Brand of the Year*, PHARMEXEC.COM, February 1, 2007.  
22 <http://www.pharmexec.com/brand-year-0>

23           74. Merck also engaged in a relentless propaganda campaign aimed at  
24 frightening and guiltig parents who failed to inoculate their children with Gardasil.

25           75. In addition to paid advertising, Merck worked with third parties to “seed”  
26 an obliging media with terrifying stories about cervical cancer in preparation for  
27 Merck’s Gardasil launch.

28           76. Prior to the FDA’s 2006 approval of Gardasil, the mainstream media –

1 under direction of Merck and its agents – dutifully reported alarming cervical cancer  
2 stories, accompanied by the promotion of an auspicious vaccine.

3 77. Merck intended its campaign to create fear and panic and a public  
4 consensus that “good mothers vaccinate” their children with Gardasil. According to  
5 Merck propagandists, the only choice was to “get the vaccine immediately” or “risk  
6 cervical or anal cancer.”

7 78. Merck aggressively and fraudulently concealed the risks of the vaccine in  
8 broadcast materials and in propaganda that it disseminated in the United States.

9 79. Merck sold and falsely promoted Gardasil knowing that, if consumers were  
10 fully informed about Gardasil’s risks and dubious benefits, almost no one would have  
11 chosen to vaccinate.

12 80. Merck negligently and fraudulently deprived parents and children of their  
13 right to informed consent.

14 81. One of Merck’s television campaigns, conducted in 2016, shamelessly used  
15 child actors and actresses, implicitly dying of cancer, looking straight into the camera  
16 and asking their parents whether or not they knew that the HPV vaccine could have  
17 protected them against the HPV virus that caused them to develop their cancers. Each  
18 actor asked the following question: “Did you know? Mom? Dad?” See “Mom, Dad, did  
19 you know?” commercial: <https://www.ispot.tv/ad/Ap1V/know-hpv-hpv-vaccination>.  
20 Merck spent \$41 million over two months on the campaign. The ads said nothing about  
21 potential side effects. Merck also distributed pamphlets via U.S. mail to doctors ahead  
22 of the ad’s release to encourage them to share it with their patients:  
23  
24  
25  
26  
27  
28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28



82. Merck’s fraudulent message was that cervical cancer and anal cancer were real-life killers of young men and women, notwithstanding the fact that the average age for development of cervical cancer is 50 years old, average age of development of anal cancer is 60 years old and that the cancer is virtually nonexistent in men and women under 20.

83. Other television marketing campaigns Merck launched falsely proclaimed that Gardasil was a “cervical cancer vaccine” and that any young girl vaccinated with Gardasil would become “one less” woman with cervical cancer. The “One Less” marketing campaign portrayed Gardasil as if there were no question as to the vaccine’s efficacy in preventing cervical cancer, and it disclosed none of Gardasil’s side effects.

84. Merck marketed Gardasil with the most aggressive campaign ever mounted to promote a vaccine, spending more on Gardasil advertising than any previous vaccine advertising campaign.

**D. Merck Used Scare Tactics and Provided Financial Incentives to Legislatures to Attempt to make the Gardasil Vaccine Mandatory for All School Children**

85. An ACIP recommendation of a vaccine, adopted by individual states, opens the door to mandates affecting as many as four million children annually.

86. With Gardasil costing \$360 for the original three-dose series (exclusive of the necessary doctor’s visits) and Gardasil 9 now priced at \$450 for two doses (again, not including the cost of doctor’s visits), Merck stood to earn billions of dollars per

1 year, in the US alone, with little marketing costs.

2 87. Prior to Gardasil’s approval in 2006, Merck was already targeting political  
3 figures to aid in the passage of mandatory vaccination laws.

4 88. As early as 2004, a group called Women in Government (“WIG”) started  
5 receiving funding from Merck and other drug manufacturers who had a financial  
6 interest in the vaccine.

7 89. With the help of WIG, Merck aggressively lobbied legislators to mandate  
8 Gardasil to all sixth-grade girls. *See Michelle Mello et al., Pharmaceutical*  
9 *Companies’ Role in State Vaccination Policymaking: The Case of Human*  
10 *Papillomavirus Vaccination*, 102 AMERICAN J PUBLIC HEALTH 893 (May 2012).

11 90. In 2006, Democratic Assembly leader Sally Lieber of California introduced  
12 a bill that would require all girls entering sixth grade to receive the Gardasil  
13 vaccination. Lieber later dropped the bill after it was revealed there was a possible  
14 financial conflict of interest.

15 91. Prior to the introduction of the bill, Lieber met with WIG representatives.  
16 In an interview, the President of WIG, Susan Crosby, confirmed that WIG funders have  
17 direct access to state legislators, in part through the organization’s Legislative Business  
18 Roundtable, of which WIG funders are a part. *See Judith Siers-Poisson, The Gardasil*  
19 *Sell Job*, in CENSORED 2009: THE TOP 25 CENSORED STORIES OF 2007-08, 246 (Peter  
20 Philips ed. 2011).

21 92. Dr. Diane Harper, a medical doctor and scientist who was hired as a  
22 principal investigator on clinical trials for Gardasil gave an interview for an article on  
23 the HPV vaccines and WIG in 2007. Harper, who had been a major presenter at a WIG  
24 meeting in 2005, stated that “the Merck representative to WIG was strongly supporting  
25 the concept of mandates later in the WIG meetings and providing verbiage on which  
26 the legislators could base their proposals.”

27 93. WIG was one of dozens of “pay to play” lobby groups that Merck  
28 mobilized to push HPV vaccine mandates.

1 94. Another group, the National Association of County and City Health  
2 Officials (NACCHO), was also pushing HPV vaccine mandates in all 50 states.

3 95. To that end, Merck made large contributions to political campaigns and  
4 legislative organizations. By February 2007, 24 states and the District of Columbia had  
5 introduced mandate legislation.

6 96. Several states passed laws allowing preteen children as young as age 12 to  
7 “consent” to vaccination with an HPV vaccine without parental consent or knowledge.

8 97. One New York state county offered children free headphones and speakers  
9 to encourage them to consent to the Gardasil vaccine. *See* Mary Holland *et al.*, THE  
10 HPV VACCINE ON TRIAL: SEEKING JUSTICE FOR A GENERATION BETRAYED 131 (2018).

11 98. Merck funneled almost \$92 million to Maryland’s Department of Health  
12 between 2012 and 2018 to promote Gardasil in Maryland schools, in a fraudulent  
13 campaign that paid school officials to deliberately deceive children and parents into  
14 believing Gardasil was mandatory for school attendance. Josh Mazer, *Maryland should*  
15 *be upfront about HPV vaccinations for children*, CAPITAL GAZETTE, August 14, 2018,  
16 at [https://www.capitalgazette.com/opinion/columns/ac-ce-column-mazer-20180814-](https://www.capitalgazette.com/opinion/columns/ac-ce-column-mazer-20180814-story.html)  
17 [story.html](https://www.capitalgazette.com/opinion/columns/ac-ce-column-mazer-20180814-story.html).

### 18 **E. Merck Pushed Gardasil Using Trusted Doctors and Third-Party** 19 **Front Groups**

20 99. In order to mobilize “third-party credibility” to push Gardasil, Merck gave  
21 massive donations to dozens of nonprofit groups to “educate” the public via “education  
22 grants.” For example, a disclaimer on American College of Obstetricians and  
23 Gynecologists’ Immunization for Women website stated that “[t]his website is  
24 supported by an independent educational grant from Merck and Sanofi Pasteur US.”

25 100. Merck offered influential doctors (also known as “key opinion leaders”)  
26 \$4,500 for every Gardasil lecture they gave.

27 101. Among the allegedly independent organizations Merck recruited to push  
28 Gardasil were the Immunization Coalition, the Allegheny County Board of Health, the

1 Eye and Ear Foundation, the Jewish Healthcare Foundation, the American Dental  
2 Association, the American College of Obstetricians and Gynecologists, and the  
3 American Cancer Society.

4 **F. Merck Has Systematically Misrepresented the Efficacy of Gardasil**  
5 **By Advertising that Gardasil Prevents Cervical Cancer When**  
6 **There Are No Clinical Studies to Support This False Claim**

7 102. Merck faced a daunting problem in convincing regulators, doctors, and the  
8 public to accept the Gardasil vaccine.

9 103. Merck recommends the vaccine for children aged 11 to 12 years old, to  
10 provide protection against a disease that, in the United States, is not generally  
11 diagnosed until a median age of 50. Moreover, in those rare instances of death, the  
12 median age is 58.

13 104. There are no studies proving that Gardasil prevents cancer.

14 105. Because it can take decades for a persistent HPV infection to proceed to  
15 development of cervical or anal cancer, and because cervical and anal cancers are so  
16 rare, a true efficacy study would require decades and likely hundreds of thousand – if  
17 not millions – of trial participants to demonstrate that eliminating certain HPV  
18 infections would actually prevent the development of cervical and anal cancer.

19 106. Merck did not want to invest the time or money necessary to perform  
20 testing that would prove that its vaccine actually worked to prevent cervical and anal  
21 cancer.

22 107. Instead, Merck persuaded regulators to allow it to use “surrogate  
23 endpoints” to support its theory that the HPV vaccines would be effective in preventing  
24 cervical and anal cancer.

25 108. The clinical trials therefore did not test whether HPV vaccines prevent  
26 cervical, anal or other cancers. Instead, Merck tested the vaccines against development  
27 of certain cervical lesions, which some researchers suspect are precursors to cancer,  
28 although the majority of these lesions – even the most serious – regress on their own.

1 See, e.g., Jin Yingji et al., *Use of Autoantibodies Against Tumor-Associated Antigens as*  
2 *Serum Biomarkers for Primary Screening of Cervical Cancer*, 8 ONCOTARGET 105425  
3 (Dec. 1, 2017); Philip Castle et al., *Impact of Improved Classification on the*  
4 *Association of Human Papillomavirus With Cervical Precancer*, 171 AMERICAN  
5 JOURNAL OF EPIDEMIOLOGY 161 (Dec. 10, 2009); Karoliina Tainio et al., *Clinical*  
6 *Course of Untreated Cervical Intraepithelial Neoplasia Grade 2 Under Active*  
7 *Surveillance: Systematic Review and Meta-Analysis*, 360 BRIT. MED. J. k499 (Jan. 16,  
8 2018).

9 109. The Department of Health and Human Services (HHS), which oversees the  
10 FDA, and which also stood to make millions of dollars on the vaccine from patent  
11 royalties, allowed the use of Merck’s proposed surrogate endpoints.

12 110. The surrogate endpoints chosen by Merck to test the efficacy of its HPV  
13 vaccine were cervical and anal intraepithelial neoplasia (CIN) grades 2 and 3 and  
14 adenocarcinoma in situ.

15 111. Merck used these surrogate endpoints even though it knew that these  
16 precursor lesions are common in young women under 25 and rarely progress to cancer.

17 112. At the time FDA approved the vaccine, Merck’s research showed only that  
18 Gardasil prevented certain lesions (the vast majority of which would have resolved on  
19 their own without intervention) and genital warts – not cancer itself, and only for a few  
20 years at that.

21 113. The use of these surrogate endpoints allowed Merck to shorten the clinical  
22 trials to a few years and gain regulatory approvals of the vaccines without any evidence  
23 the vaccines would prevent cancer in the long run.

24 114. Merck’s advertisements assert that the HPV vaccine prevents cervical  
25 cancer. For example, in a presentation to medical doctors, Merck proclaimed: “Every  
26 year that increases in coverage [of the vaccine] are delayed, another 4,400 women will  
27 go on to develop cervical cancer.” The presentation goes on to tell doctors that women  
28 who do not get the vaccine will go on to develop cancer.

1 115. Merck's foundational theory that HPV alone causes cervical and anal  
2 cancer, while dogmatically asserted, is not proven.

3 116. Research indicates that cervical and anal cancer is a multi-factor disease  
4 with persistent HPV infections seeming to play a role, along with many other  
5 environmental and genetic factors, including smoking cigarettes or exposure to other  
6 toxic smoke sources, long-term use of oral contraceptives, nutritional deficiencies,  
7 multiple births (especially beginning at an early age), obesity, inflammation, and other  
8 factors. Not all cervical and anal cancer is associated with HPV types in the vaccines  
9 and not all cervical and anal cancer is associated with HPV at all.

10 117. Despite the lack of proof, Merck claimed that Gardasil could eliminate  
11 cervical and anal cancer and other HPV-associated cancers.

12 118. However, *Merck knows* that the Gardasil vaccines cannot eliminate all  
13 cervical and anal cancer or any other cancer that may be associated with HPV.

14 119. Even assuming the Gardasil vaccine is effective in preventing infection  
15 from the four to nine vaccine-targeted HPV types, the results may be short term, not  
16 guaranteed, and ignore the 200 or more other types of HPV not targeted by the vaccine,  
17 and some of which already have been associated with cancer.

18 120. Even assuming these vaccine-targets are the types solely responsible for  
19 100 percent of cervical and anal cancer – which they are not – the vaccines have not  
20 been followed long enough to prove that Gardasil protects girls and boys from cancer  
21 that would strike them 40 years later.

22 121. Under Merck's hypothetical theory, the reduction of pre-cancerous lesions  
23 should translate to fewer cases of cervical and anal cancer in 30 to 40 years.

24 122. Cervical and anal cancer takes decades to develop and there are no studies  
25 that prove the Gardasil vaccines prevent cancer.

26 123. In January 2020, a study from the UK raised doubts about the validity of  
27 the clinical trials in determining the vaccine's potential to prevent cervical cancer. The  
28 analysis, carried out by researchers at Newcastle University and Queen Mary

1 University of London, revealed many methodological problems in the implementation  
2 of the Phase 2 and 3 trials, leading to uncertainty regarding understanding the  
3 effectiveness of HPV vaccination. *See* Claire Rees et al., *Will HPV Vaccine Prevent*  
4 *Cancer?* J. OF THE ROYAL SOC. OF MED. 1-15 (2020).

5 124. As Dr. Tom Jefferson of the Centre for Evidence-Based Medicine pointed  
6 out: “The reason for choosing vaccination against HPV was to prevent cancer but  
7 there’s no clinical evidence to prove it will do that.”

8 125. Gardasil has never been proven to prevent cervical or any other kind of  
9 cancer.

10 126. Yet Merck has marketed the Gardasil vaccines as if there is no question  
11 regarding their efficacy at preventing cervical and anal cancer. In reality, they are at  
12 best protective against only four to nine of the over 200 strains of the human  
13 papillomavirus.

14 **G. The Gardasil Vaccines Contain Numerous Hazardous Ingredients,**  
15 **Including At Least One Ingredient Merck Failed to Disclose to**  
16 **Regulators and the Public**

17 **i. Gardasil Contains A Toxic Aluminum Adjuvant**

18 127. To stimulate an enhanced immune response that allegedly *might possibly*  
19 last for 50 years, Merck added to the Gardasil vaccine a particularly toxic aluminum-  
20 containing adjuvant – Amorphous Aluminum Hydroxyphosphate Sulfate (“AAHS”).

21 128. Aluminum is a potent neurotoxin that can result in very serious harm.

22 129. The original Gardasil vaccine contains 225 micrograms of AAHS and  
23 Gardasil 9 contains 500 micrograms of AAHS.

24 130. Federal law requires that manufacturers cannot add adjuvants to vaccines  
25 that have not been proven safe. 21 C.F.R. § 610.15(a).

26 131. AAHS has never been proven safe. AAHS is a recent proprietary blend of  
27 aluminum and other unknown ingredients developed by Merck and used in Merck  
28 vaccines, including Gardasil. Prior vaccines have used a different aluminum

1 formulation.

2 132. Peer-reviewed studies show that aluminum binds to non-vaccine proteins,  
3 including the host's own proteins, or to latent viruses, triggering autoimmune and other  
4 serious conditions. See Darja Kanduc, *Peptide Cross-reactivity: The Original Sin of*  
5 *Vaccines*, 4 FRONTIERS IN BIOSCIENCE 1393 (June 2012).

6 133. Aluminum, including AAHS, has been linked to scores of systemic side  
7 effects including, but not limited to: impairing cognitive and motor function; inducing  
8 autoimmune interactions; increasing blood brain barrier permeability; inducing  
9 macrophagic myofascitis in muscle; blocking neuronal signaling; interrupting cell-to-  
10 cell communications; corrupting neuronal-glial interactions; interfering with synaptic  
11 transmissions; altering enzyme function; impairing protein function; fostering  
12 development of abnormal tau proteins; and altering DNA.

13 **ii. Merck Lied About a Secret DNA Adjuvant Contained in**  
14 **The Gardasil Vaccines**

15 134. Merck has repeatedly concealed or incorrectly identified Gardasil  
16 ingredients to the FDA and the public.

17 135. Merck lied both to the FDA and the public about including a secret and  
18 potentially hazardous ingredient, HPV LI-DNA fragments, in Gardasil. These DNA  
19 fragments could act as a Toll-Like Receptor 9 ("TLR9") agonist – further adjuvanting  
20 the vaccine and making it more potent. Merck used this hidden adjuvant to prolong the  
21 immunological effects of the vaccine, but illegally omitted it from its list of substances  
22 and ingredients in the vaccine.

23 136. Dr. Sin Hang Lee has opined that, without adding the TLR9 agonist,  
24 Gardasil would not be immunogenic. The DNA fragments bound to the AAHS  
25 nanoparticles act as the TLR9 agonist in both Gardasil and Gardasil 9 vaccines,  
26 creating the strongest immune-boosting adjuvant in use in any vaccine.

27 137. On multiple occasions, Merck falsely represented to the FDA and others,  
28 including regulators in other countries, that the Gardasil vaccine did not contain viral

1 DNA, ignoring the DNA fragments.

2 138. This DNA adjuvant is not approved by the FDA and Merck does not list it  
3 among the ingredients as federal law requires. See 21 C.F.R. § 610.61(o) (requiring  
4 that adjuvants be listed on biologics' labeling). Even if not an adjuvant, the DNA  
5 fragments should have been listed because they represent a safety issue. 21 C.F.R.  
6 §610.61(n).

7 139. It is unlawful for vaccine manufacturers to use an experimental and  
8 undisclosed adjuvant.

9 140. When independent scientists found DNA fragments in every Gardasil vial  
10 tested, from all over the world, Merck at first denied, and then finally admitted, the  
11 vaccine does indeed include HPV L1-DNA fragments.

12 141. Tellingly, Merck entered into a business arrangement with Idera  
13 Pharmaceuticals in 2006 to explore DNA adjuvants to further develop and  
14 commercialize Idera's toll-like receptors in Merck's vaccine program.

15 142. To this day, the Gardasil package inserts do not disclose that DNA  
16 fragments remain in the vaccine.

17 143. Dr. Lee also found HPV DNA fragments from the Gardasil vaccine in post-  
18 mortem spleen and blood samples taken from a young girl who died following  
19 administration of the vaccine. See Sin Hang Lee, *Detection of Human Papillomavirus*  
20 *L1 Gene DNA Fragments in Postmortem Blood and Spleen After Gardasil*  
21 *Vaccination—A Case Report*, 3 ADVANCES IN BIOSCIENCE AND BIOTECHNOLOGY 1214  
22 (December 2018).

23 144. Those fragments appear to have played a role in the teenager's death.

24 145. The scientific literature suggests there are grave and little-understood risks  
25 attendant to injecting DNA into the human body.

26 **iii. Gardasil Contains Borax**

27 146. Gardasil contains sodium borate (borax). Borax is a toxic chemical and  
28 may have long-term toxic effects.

1 147. Merck has performed no studies to determine the impact of injecting borax  
2 into millions of young children or adults.

3 148. Sodium borate is known to have adverse effects on male reproductive  
4 systems in rats, mice, and dogs. Furthermore, borax causes increased fetal deaths,  
5 decreased fetal weight, and increased fetal malformations in rats, mice, and rabbits.

6 149. The European Chemical Agency requires a “DANGER!” warning on borax  
7 and states that borax “may damage fertility or the unborn child.”

8 150. The Material Safety Data Sheet (“MSDS”) for sodium borate states that  
9 sodium borate “[m]ay cause adverse reproductive effects” in humans.

10 151. The FDA has banned borax as a food additive in the United States, and yet  
11 allows Merck to use it in the Gardasil vaccine without any proof of safety.

12 **iv. Gardasil Contains Polysorbate 80**

13 152. Gardasil contains Polysorbate 80.

14 153. Polysorbate 80 crosses the blood-brain barrier.

15 154. Polysorbate 80 is used in drugs to open up the blood brain barrier in order  
16 to allow the active ingredients in a drug to reach the brain and to elicit the intended  
17 response. It acts as an emulsifier for molecules like AAHS and aluminum, enabling  
18 those molecules to pass through resistive cell membranes.

19 155. Polysorbate 80 is associated with many health injuries, including,  
20 anaphylaxis, infertility and cardiac arrest.

21 156. Polysorbate 80 was implicated as a cause, possibly with other components,  
22 of anaphylaxis in Gardasil recipients in a study in Australia. *See* Julia Brotherton et al.,  
23 *Anaphylaxis Following Quadrivalent Human Papillomavirus Vaccination*, 179  
24 *CANADIAN MEDICAL ASSOC. J.* 525 (September 9, 2008). Merck never tested  
25 Polysorbate 80 for safety in vaccines.

26 **v. Gardasil Contains Genetically Modified Yeast**

27 157. Gardasil contains genetically modified yeast.

28 158. Studies have linked yeast with autoimmune conditions. *See, e.g.*, Maurizo

1 Rinaldi et al., *Anti-Saccharomyces Cerevisiae Autoantibodies in Autoimmune Diseases:*  
2 *from Bread Baking to Autoimmunity*, 45 CLINICAL REVIEWS IN ALLERGY AND  
3 IMMUNOLOGY 152 (October 2013).

4 159. Study participants with yeast allergies were excluded from Gardasil clinical  
5 trials.

6 160. Merck has performed no studies to determine the safety of injecting yeast  
7 into millions of children and young adults.

8 **H. As it Did in Vioxx, In Orchestrating and Conducting Its Clinical**  
9 **Trials for Gardasil, Merck Concealed Risks to Falsely Enhance the**  
10 **Safety Profile of Gardasil**

11 161. Merck engaged in wholesale fraud during its safety and efficacy clinical  
12 studies.

13 162. In order to obtain its Gardasil license, Merck implemented its studies  
14 purposefully to conceal adverse events and exaggerate efficacy.

15 163. Merck sold Gardasil to the public falsely claiming that pre-licensing safety  
16 tests proved it to be effective and safe.

17 164. In fact, Merck's own pre-licensing studies showed Gardasil to be of  
18 doubtful efficacy and dangerous.

19 165. The dishonesty in the clinical tests has led many physicians to recommend  
20 the vaccination, under false assumptions.

21 166. The clinical trials clearly demonstrated that the risks of both Gardasil and  
22 Gardasil 9 vastly outweigh any proven or theoretical benefits.

23 167. Merck deliberately devised the Gardasil protocols to conceal evidence of  
24 chronic conditions such as autoimmune diseases, menstrual cycle problems and death  
25 associated with the vaccine during the clinical studies.

26 168. Merck employed deceptive means to cover up injuries that study group  
27 participants suffered.

28 169. In early 2018, Lars Jørgensen, M.D., Ph.D. and Professor Peter Gøtzsche,

1 M.D. (then with the Nordic Cochrane Centre), and Professor Tom Jefferson, M.D., of  
2 the Centre for Evidence-Based Medicine, published a study indexing all known  
3 industry and non-industry HPV vaccine clinical trials and were disturbed to find that  
4 regulators such as the FDA and EMA (European Medicines Agency) assessed as little  
5 as half of all available clinical trial results when approving the HPV vaccines. Lars  
6 Jørgensen et al., *Index of the Human Papillomavirus (HPV) Vaccine Industry Clinical*  
7 *Study Programmers and Non-Industry Funded Studies: a Necessary Basis to Address*  
8 *Reporting Bias in a Systematic Review*, 7 SYSTEMATIC REVIEWS (January 18, 2018).

9 170. Per the indexing study discussed above, Merck appears to have kept a  
10 number of its clinical trial results secret. Moreover, it appears that Merck reported only  
11 those findings that support its own agenda.

12 171. Three separate reviews of the Gardasil vaccine by the Cochrane  
13 Collaboration found that the trial data were “largely inadequate.”

14 172. According to Dr. Tom Jefferson, “HPV [vaccine] harms have not been  
15 properly studied.”

16 173. In 2019, numerous medical professionals published an article in the British  
17 Medical Journal outlining the flaws and incomplete nature of the publications  
18 discussing Merck’s Gardasil clinical trials. The authors issued a “call to action” for  
19 independent researchers to reanalyze or “restore the reporting of multiple trials in  
20 Merck’s clinical development program for quadrivalent human papillomavirus (HPV)  
21 vaccine (Gardasil) vaccine.” Peter Doshi et al., *Call to Action: RIAT Restoration of*  
22 *Previously Unpublished Methodology in Gardasil Vaccine Trials*, 346 BRIT. MED. J.  
23 2865 (2019). The authors explained that the highly influential publications of these  
24 studies, which formed the basis of Gardasil’s FDA approval, “incompletely reported  
25 important methodological details and inaccurately describe the formulation that the  
26 control arm received, necessitating correction of the record.” *Id.* The authors  
27 explained that, while the publications claimed the clinical trials of Gardasil were  
28 “placebo-controlled,” “participants in the control arm of these trials did not receive an

1 inert substance, such as saline injection. Instead, they received an injection containing  
2 [AAHS], a proprietary adjuvant system that is used in Gardasil to boost immune  
3 response.” *Id.*

4 174. The researchers further opined that “the choice of AAHS-containing  
5 controls complicates the interpretation of efficacy and safety results in trials ... We  
6 consider the omission in journal articles, of any rationale for the selection of AAHS-  
7 containing control, to be a form of incomplete reporting (of important methodological  
8 details) and believe the rationale must be reported. We also consider that use of the  
9 term ‘placebo’ to describe an active comparator like AAHS inaccurately describes the  
10 formulation that the control arm received, and constitutes an important error that  
11 requires correction.” *Id.*

12 175. The authors pointed out that Merck’s conduct “raises ethical questions  
13 about trial conduct as well” and that they and other scientists would need to review the  
14 Gardasil clinical trial raw data, in order to be able to analyze the safety and adverse  
15 event profile of Gardasil meaningfully and independently. *Id.*

16 **i. Small Clinical Trials**

17 176. Although nine to 12-year-olds are the primary target population for HPV  
18 vaccines, Merck used only a small percentage of this age group in the clinical trials.  
19 Protocol 018 was the only protocol comparing children receiving a vaccine to those  
20 who did not. In that study, Merck looked at results of fewer than 1,000 children 12 and  
21 younger for a vaccine targeting billions of boys and girls in that age group over time.  
22 In Protocol 018, 364 girls and 332 boys (696 children) were in the vaccine cohort,  
23 while 199 girls and 173 boys (372 children) received a non-aluminum control.

24 177. The small size of this trial means that it was incapable of ascertaining all  
25 injuries that could occur as a result of the vaccine.

26 **ii. Merck Used a Highly Toxic “Placebo” to Mask Gardasil**  
27 **Injuries**

28 178. Instead of comparing health outcomes among volunteers in the Gardasil

1 study group to health outcomes among volunteers receiving an inert placebo, Merck  
2 purposefully used a highly toxic placebo as a control in order to conceal Gardasil's  
3 risks in all trials using comparators with the exception of Protocol 018, where only 372  
4 children received a non-saline placebo containing everything in the vaccine except the  
5 adjuvant and antigen.

6 179. Comparing a new product against an inactive placebo provides an accurate  
7 picture of the product's effects, both good and bad. The World Health Organization  
8 ("WHO") recognizes that using a toxic comparator as a control (as Merck did here)  
9 creates a "methodological disadvantage." WHO states that "it may be difficult or  
10 impossible to assess the safety" of a vaccine when there is no true placebo.

11 180. Merck deliberately used toxic "placebos" in the control group, in order to  
12 mask harms caused by Gardasil to the study group.

13 181. Instead of testing Gardasil against a control with a true inert placebo,  
14 Merck tested its vaccine in almost all clinical trials against its highly neurotoxic  
15 aluminum adjuvant, AAHS.

16 182. Merck gave neurotoxic aluminum injections to approximately 10,000 girls  
17 and young women participating in Gardasil trials, to conceal the dangers of Gardasil  
18 vaccines.

19 183. Merck never safety tested AAHS before injecting it into thousands of girls  
20 and young women in the control groups and the girls and young women were not told  
21 they could receive an aluminum "placebo." Merck told the girls that they would  
22 receive either the vaccine or a safe inert placebo.

23 184. Merck violated rules and procedures governing clinical trials when it lied  
24 to the clinical study volunteers, telling them that the placebo was an inert saline  
25 solution – when in reality the placebo contained the highly neurotoxic aluminum  
26 adjuvant AAHS.

27 185. AAHS provoked terrible injuries and deaths in a number of the study  
28 participants when Merck illegally dosed the control group volunteers with AAHS.

1 186. Since the injuries in the Gardasil group were replicated in the AAHS  
2 control group, this scheme allowed Merck to falsely conclude that Gardasil’s safety  
3 profile was comparable to the “placebo.”

4 187. The scheme worked and enabled Merck to secure FDA licensing.

5 188. Merck lied to the FDA when it told public health officials that it had used a  
6 saline placebo in Protocol 018.

7 189. There was no legitimate public health rationale for Merck’s failure to use a  
8 true saline placebo control in the original Gardasil clinical trials. At that time, no other  
9 vaccine was yet licensed for the four HPV strains Gardasil was intended to prevent.

10 190. A small handful of girls in a subsequent Gardasil 9 trial group, may have  
11 received the saline placebo, but only after they had already received three doses of  
12 Gardasil for the Gardasil 9 trial.

13 **iii. Merck Used Exclusionary Criteria to Further Conceal**  
14 **Gardasil Risks**

15 191. Merck also manipulated the Gardasil studies by excluding nearly half of  
16 the original recruits to avoid revealing the effects of the vaccine on vulnerable  
17 populations.

18 192. After recruiting thousands of volunteers to its study, Merck excluded all  
19 women who had admitted to vulnerabilities that might be aggravated by the vaccine,  
20 such as abnormal Pap tests or a history of immunological or nervous system disorders.

21 193. Women could also be excluded for “[a]ny condition which in the opinion  
22 of the investigator might interfere with the evaluation of the study objectives.”

23 194. Merck’s protocol had exclusion criteria for subjects with allergies to  
24 vaccine ingredients including aluminum (AAHS), yeast, and the select enzymes. For  
25 most of these ingredients, there are limited resources for the public to test for such  
26 allergies in advance of being vaccinated.

27 195. Merck excluded anyone with serious medical conditions from the Gardasil  
28 clinical trials, even though CDC recommends the Gardasil vaccine for everyone,

1 regardless of whether or not they suffer from a serious medical condition.

2 196. Merck sought to exclude from the study all subjects who might be part of  
3 any subgroup that would suffer injuries or adverse reactions to any of Gardasil's  
4 ingredients.

5 197. The study exclusion criteria are not listed as warnings on the package  
6 inserts and the package insert for Gardasil only mentions an allergy to yeast or to a  
7 previous dose of Gardasil as a contraindication, rather than an allergy to any other  
8 component. Nonetheless, for most of the ingredients, it is almost impossible to  
9 determine if such an allergy exists prior to being vaccinated and Merck does not  
10 recommend allergy testing before administering the vaccine.

11 198. Instead of testing the vaccine on a population representative of the cross-  
12 section of humans who would receive the approved vaccine, Merck selected robust,  
13 super-healthy trial participants, who did not reflect the general population, in order to  
14 mask injurious effects on all the vulnerable subgroups that now receive the vaccine.  
15 Therefore, the population tested in the clinical trials was a much less vulnerable  
16 population than the population now receiving Gardasil.

17 **iv. Merck Deceived Regulators and The Public by Classifying**  
18 **Many Serious Adverse Events, Which Afflicted Nearly**  
19 **Half of All Study Participants, As Coincidences**

20 199. Because Merck did not use a true placebo, determining which injuries were  
21 attributable to the vaccine and which were attributable to unfortunate coincidence was  
22 entirely within the discretion of Merck's paid researchers.

23 200. In order to cover up and conceal injuries from its experimental vaccine,  
24 Merck, during the Gardasil trials, employed a metric, "new medical conditions," that  
25 allowed the company to dismiss and fraudulently conceal infections, reproductive  
26 disorders, neurological symptoms, and autoimmune conditions, which affected a  
27 troubling 50 percent of all clinical trial participants.

28 201. Merck's researchers systematically dismissed reports of serious adverse  
events from 49 percent of trial participants in order to mask the dangers of the vaccine.

1 202. Instead of reporting these injuries as “adverse events,” Merck dismissed  
2 practically all of these illnesses and injuries as unrelated to the vaccine by classifying  
3 them under its trashcan metric “new medical conditions,” a scheme Merck could get  
4 away with only because it used a “spiked” (poisonous) placebo, that was yielding  
5 injuries at comparable rates.

6 203. Merck’s use of a toxic placebo allowed the company to conceal from the  
7 public an epidemic of autoimmune diseases and other injuries and deaths associated  
8 with its multi-billion-dollar HPV vaccine.

9 204. Because Merck conducted its studies without a true placebo, Merck  
10 investigators had wide discretion to decide what constituted an adverse event and used  
11 that power to dismiss a wave of grave vaccine injuries, injuries that sickened half of the  
12 trial volunteers, as coincidental.

13 205. Almost half (49 percent) of all trial participants, regardless of whether they  
14 received the vaccine or Merck’s toxic placebo, reported adverse events, including  
15 serious illnesses such as blood, lymphatic, cardiac, gastrointestinal, immune,  
16 musculoskeletal, reproductive, neurological and psychological conditions, chronic  
17 illnesses such as thyroiditis, arthritis and multiple sclerosis, and conditions requiring  
18 surgeries. *See, e.g., Nancy B. Miller, Clinical Review of Biologics License Application*  
19 *for Human Papillomavirus 6, 11, 16, 18 L1 Virus Like Particle Vaccine (S. cerevisiae)*  
20 *(STN 125126 GARDASIL), manufactured by Merck, Inc. at 393-94 (Table 302) (June*  
21 *8, 2006).*

22 **v. Merck Manipulated the Study Protocols to Block**  
23 **Participants and Researchers from Reporting Injuries and**  
24 **Devised the Studies to Mask Any Long-Term Adverse**  
**Events**

25 206. Merck adopted multiple strategies to discourage test subjects from  
26 reporting injuries.

27 207. Merck provided Vaccination Report Cards to a limited number of trial  
28 participants. For example, in Protocol 015, only approximately 10 percent of

1 participants – all in the United States, despite trial sites worldwide – received  
2 Vaccination Report Cards to memorialize reactions in the first few days following  
3 injections.

4 208. Furthermore, the report cards only included categories of “Approved  
5 Injuries” mainly jab site reactions (burning, itching, redness, bruising) leaving no room  
6 to report more serious unexplained injuries such as autoimmune diseases. In fact, they  
7 were devised for the purposes of reporting non-serious reactions only.

8 209. Furthermore, Merck instructed those participants to record information for  
9 only 14 days following the injection.

10 210. In this way, Merck foreclosed reporting injuries with longer incubation  
11 periods or delayed diagnostic horizons.

12 211. Abbreviated reporting periods were part of Merck’s deliberate scheme to  
13 conceal chronic conditions such as autoimmune or menstrual cycle problems, and  
14 premature ovarian failure, all of which have been widely associated with the vaccine,  
15 but would be unlikely to show up in the first 14 days following injection.

16 212. Merck researchers did not systematically collect adverse event data, from  
17 the trials, which were spread out over hundreds of test sites all over the world.

18 213. To conceal the dangerous side effects of its vaccine, Merck purposely did  
19 not follow up with girls who experienced serious adverse events during the Gardasil  
20 clinical trials.

21 214. Merck failed to provide the trial subjects a standardized questionnaire  
22 checklist of symptoms, to document a comparison of pre- and post-inoculation  
23 symptoms.

24 215. To discourage its clinicians from reporting adverse events, Merck made the  
25 paperwork reporting requirements for supervising clinicians, onerous and time-  
26 consuming, and refused to pay  
27 investigators additional compensation for filling out the paperwork.

28 216. Thus, Merck disincentivized researchers from reviewing participants’

1 medical records even when the participant developed a “serious medical condition that  
2 meets the criteria for serious adverse experiences” as described in the protocol.

3 217. Merck granted extraordinary discretion to its researchers to determine what  
4 constituted a reportable adverse event, while incentivizing them to report nothing and  
5 to dismiss all injuries as unrelated to the vaccine.

6 218. Merck used subpar, subjective data collection methods, relying on  
7 participants’ recollections and the biased viewpoints of its trial investigators.

8 219. Merck downplayed the incidence of serious injuries and used statistical  
9 gimmickry to under-report entries.

10 220. During its Gardasil clinical trials, Merck failed to adequately capture and  
11 properly code adverse events and symptoms, including but not limited to adverse  
12 events and symptoms that were indicative of autoimmune or neurological injuries,  
13 including but not limited to POTS and CRPS, so as to prevent the medical community,  
14 regulators and patients from learning about these adverse events and to avoid the  
15 responsibility of having to issue appropriate warnings concerning these adverse events.

16 **vi. Merck Deceived Regulators and the Public About Its**  
17 **Pivotal Gardasil Clinical Trial (Protocol 018)**

18 221. Merck tested Gardasil and Gardasil 9 in some 50 clinical trials, each one  
19 called a “Protocol.” However, results for many of these studies are not available to the  
20 public or even to the regulators licensing Gardasil. *See* Lars Jørgensen, *et al.*, *Index of*  
21 *the Human Papillomavirus (HPV) Vaccine Industry Clinical Study Programmers and*  
22 *Non-Industry Funded Studies: a Necessary Basis to Address Reporting Bias in a*  
23 *Systematic Review*, 7 SYSTEMATIC REVIEWS 8 (January 18, 2018).

24 222. Gardasil’s most important clinical trial was Protocol 018. The FDA  
25 considered Protocol 018 the pivotal trial upon which Gardasil licensing approvals  
26 hinged, because FDA believed 1) it was the only trial where Merck used a “true saline  
27 placebo,” and 2) it was the only trial with a comparator group that included girls aged  
28 11 to 12 – the target age for the Gardasil vaccine. *See* Transcript of FDA Center For

1 Biologics Evaluation And Research VRBPAC Meeting, May 18, 2006, at 93 (Dr.  
2 Nancy Miller).

3 223. Merck lied to regulators, to the public and to subjects in its clinical trials by  
4 claiming that the Protocol 018 “placebo” group received an actual saline or inert  
5 placebo.

6 224. When the FDA approved Gardasil, it described the Protocol 018 control as  
7 a “true saline placebo.”

8 225. The FDA declared that the Protocol 018 trial was “of particular interest”  
9 because Merck used a true saline placebo instead of the adjuvant as a control.

10 226. Merck told regulators that it gave a “saline placebo” to only one small  
11 group of approximately 600 nine to 15-year-old children.

12 227. In fact, Merck did not give even this modest control group a true saline  
13 placebo, but rather, the group members were given a shot containing “the carrier  
14 solution” – a witch’s brew of toxic substances including polysorbate 80, sodium borate  
15 (borax), genetically modified yeast, L-histidine, and possibly a fragmented DNA  
16 adjuvant.

17 228. The only components of Gardasil the control group did not receive were  
18 the HPV antigens and the aluminum adjuvant.

19 229. Despite the witches’ brew of toxic chemicals in the carrier solution, those  
20 children fared much better than any other study or control group participants, all of  
21 whom received the AAHS aluminum adjuvant.

22 230. Only 29 percent of the vaccinated children and 31 percent of control  
23 recipients in Protocol 018 reported new illnesses from Day 1 through Month 12,  
24 compared to an alarming 49.6 percent of those vaccinated and 49 percent of AAHS  
25 controls in the “pooled group” (composed of some 10,000 young women and with the  
26 other participants combined) from Day 1 only through Month 7 (not 12). Because the  
27 pooled group also included Protocol 018, even those numbers may not be accurate with  
28 respect to those who received either a vaccine with a full dose of AAHS or those who

1 received an AAHS control.

2 231. Few of the participants in the Protocol 018 control group got systemic  
3 autoimmune diseases, compared to 2.3 percent (1 in every 43) in the pooled group. In a  
4 follow-up clinical review in 2008, the FDA identified three girls in the carrier-solution  
5 group with autoimmune disease. Based on the number of girls in the placebo group as  
6 stated in the original 2006 clinical review, fewer than 1 percent of girls in the carrier  
7 solution group reported autoimmune disease.

8 232. In order to further deceive the public and regulators, upon information and  
9 belief, Merck cut the dose of aluminum adjuvant in half when it administered the  
10 vaccine to the nine to fifteen-year-old children in its Protocol 018 study group.

11 233. As a result, this group showed significantly lower “new medical  
12 conditions” compared to other protocols.

13 234. Upon information and belief, Merck pretended that the vaccinated children  
14 in the Protocol 018 study group received the full dose adjuvant by obfuscating the  
15 change in formulation in the description.

16 235. Upon information and belief, Merck had cut the adjuvant in half, knowing  
17 that this would artificially and fraudulently lower the number of adverse events and  
18 create the illusion that the vaccine was safe.

19 236. Upon information and belief, Merck lied about this fact to the FDA.

20 237. The data from that study therefore do not support the safety of the Gardasil  
21 formulation since Merck was not testing Gardasil but a far less toxic formulation.

22 238. Upon information and belief, Merck was testing a product with only half  
23 the dose of Gardasil’s most toxic component.

24 239. Upon information and belief, this is blatant scientific fraud, which  
25 continues to this day because this is the study upon which current vaccine safety and  
26 long-term efficacy assurances are based.

27 240. As set forth above, upon information and belief, Merck’s deception served  
28 its purpose: Only 29 percent of the vaccinated children in Protocol 018 reported new

1 illness, compared to an alarming 49.6 percent in the pooled group to receive the full  
2 dose adjuvant in the vaccine.

3 **I. Contrary to Merck’s Representations, Gardasil May Actually**  
4 **Cause and Increase the Risk of Cervical and Other Cancers**

5 241. Gardasil’s label states, “Gardasil has not been evaluated for potential to  
6 cause carcinogenicity or genotoxicity.” The Gardasil 9 label states: “GARDASIL9 has  
7 not been evaluated for the potential to cause carcinogenicity, genotoxicity or  
8 impairment of male fertility.

9 242. Peer-reviewed studies, including CDC’s own studies, have suggested that  
10 the suppression of the HPV strains targeted by the Gardasil vaccine may actually open  
11 the ecological niche for replacement by more virulent strains. *See Fangjian Guo et al.,*  
12 *Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young*  
13 *adult women (20–26 years)*, 11 HUMAN VACCINES & IMMUNOTHERAPEUTICS 2337  
14 (October 2015); Sonja Fischer et al., *Shift in prevalence of HPV types in cervical*  
15 *cytology specimens in the era of HPV vaccinations*, 12 ONCOLOGY LETTERS 601  
16 (2016); J. Lyons-Weiler, *Biased Cochrane Report Ignores Flaws in HPV Vaccine*  
17 *Studies, and Studies of HPV Type Replacement*, (May 18, 2018). In other words,  
18 Gardasil may increase the chances of getting cancer.

19 243. In short, the Gardasil vaccines, which Merck markets as anti-cancer  
20 products, may themselves cause cancer or mutagenetic changes that can lead to cancer.

21 244. Merck concealed from the public data from its clinical trials indicating that  
22 the vaccines enhance the risk of cervical cancers in many women.

23 245. Merck’s study showed that women exposed to HPV before being  
24 vaccinated were 44.6 percent more likely to develop cancerous lesions compared to  
25 unvaccinated women, even within a few years of receiving the vaccine.

26 246. In other words, Merck’s studies suggest that its HPV vaccines may cause  
27 cancer in women who have previously been exposed to HPV, particularly if they also  
28 have a current infection.

1 247. In some studies, more than 30 percent of girls show evidence of exposure  
2 to HPV before age ten, from casual exposures, unwashed hands or in the birth canal.  
3 Flora Bacopoulou et al., *Genital HPV in Children and Adolescents: Does Sexual*  
4 *Activity Make a Difference?*, 29 JOURNAL OF PEDIATRIC & ADOLESCENT GYNECOLOGY  
5 228 (June 2016).

6 248. Even in light of the data demonstrating that Gardasil can increase the risk  
7 of cancer in girls who previously have been exposed to HPV, in order to increase  
8 profits, Merck's Gardasil labels and promotional material do not inform patients and  
9 medical doctors of this important risk factor.

10 249. Some clinical trial participants have developed cancer, including cervical  
11 cancer.

12 250. Numerous women have reported a sudden appearance of exceptionally  
13 aggressive cervical cancers following vaccination.

14 251. Cervical cancer rates are climbing rapidly in all the countries where  
15 Gardasil has a high uptake.

16 252. An Alabama study shows that the counties with the highest Gardasil  
17 uptakes also had the highest cervical cancer rates.

18 253. After the introduction of HPV Vaccine in Britain, cervical cancer rates  
19 among young women aged 25 to 29 has risen 54 percent.

20 254. In Australia, government data reveals there has been a sharp increase in  
21 cervical cancer rates in young women following the implementation of the Gardasil  
22 vaccine. The most recent data reveal that, 13 years after Gardasil was released and  
23 pushed upon teenagers and young adults, there has been a 16 percent increase in 25 to  
24 29 year-olds and a 30 percent increase in 30 to 34 year-old girls contracting cervical  
25 cancer, corroborating the clinical trial data that Gardasil may *increase* the risk of  
26 cervical cancer, particularly in patients who had previous HPV infections. Meanwhile,  
27 rates are decreasing for older women (who have not been vaccinated).

28 255. In addition to the belief that Gardasil may create and open an ecological

1 niche for replacement by more virulent strains of HPV, resulting in the increase of  
2 cervical cancers as outlined above, in light of Merck’s false advertising that Gardasil  
3 prevents cervical cancer, young women who have received Gardasil are foregoing  
4 regular screening and Pap tests in the mistaken belief that HPV vaccines have  
5 eliminated all their risks.

6 256. Cervical screening is proven to reduce the cases of cervical cancer, and  
7 girls who have taken the vaccine are less likely to undergo cervical screenings.

8 257. Data show that girls who received HPV vaccines before turning 21 are far  
9 less likely to get cervical cancer screening than those who receive the vaccines after  
10 turning 21.

11 258. The cervical screening is more cost effective than vaccination alone or  
12 vaccination with screening.

13 259. Therefore, Pap tests, which detect cervical tissue abnormalities, and HPV  
14 DNA testing are the most effective frontline public health response to cervical health.

15 **J. Merck has Concealed the Fact that Gardasil Induces and Increases**  
16 **the Risk of Autoimmune Diseases, and Other Injuries, Including**  
17 **But Not Limited to, Postural Orthostatic Tachycardia Syndrome,**  
18 **Chronic Fatigue Syndrome, Neuropathy, Fibromyalgia and**  
**Dysautonomia**

19 260. Gardasil induces and increases the risk of autoimmune disease.

20 261. Gardasil has been linked to a myriad of autoimmune disorders, including  
21 but not limited, to: Guillain–Barré syndrome (“GBS”), postural orthostatic tachycardia  
22 syndrome (“POTS”), Orthostatic Intolerance (“OI”), chronic inflammatory  
23 demyelinating polyneuropathy (“CDIP”), small fiber neuropathy (“SNF”), systemic  
24 lupus erythematosus (“SLE”), immune thrombocytopenic purpura (“ITP”), multiple  
25 sclerosis (“MS”), acute disseminated encephalomyelitis (“ADEM”), antiphospholipid  
26 syndrome (“APS”), transverse myelitis, rheumatoid arthritis, interconnective tissue  
27 disorder, autoimmune pancreatitis (“AIP”) and autoimmune hepatitis.

28 262. Gardasil has also been linked to a myriad of diseases and symptoms that

1 are associated with induced-autoimmune disease, including for example, fibromyalgia,  
2 dysautonomia, premature ovarian failure, chronic fatigue syndrome (“CFS”), chronic  
3 regional pain syndrome (“CRPS”), cognitive dysfunction, migraines, severe headaches,  
4 persistent gastrointestinal discomfort, widespread pain of a neuropathic character,  
5 encephalitis syndrome, autonomic dysfunction, joint pain, and brain fog.

6 263. In a 2015 textbook, *VACCINES AND AUTOIMMUNITY*, edited by Dr. Yehuda  
7 Shoenfeld, the father of autoimmunology research, and many of the world’s leading  
8 autoimmunity experts, the scientists concluded that Gardasil can cause autoimmune  
9 disorders because of the vaccine’s strong immune stimulating ingredients. *See* Lucija  
10 Tomljenovic & Christopher A. Shaw, *Adverse Reactions to Human Papillomavirus*  
11 *Vaccines*, *VACCINES & AUTOIMMUNITY* 163 (Yehuda Shoenfeld et al. eds., 2015).

12 264. Medical experts have opined that the mixture of adjuvants contained in  
13 vaccines, in particular in the Gardasil vaccines, is responsible for post-vaccination  
14 induced autoimmune diseases in select patients. The risks have become so prolific that  
15 medical experts have coined a new umbrella syndrome – Autoimmune/Inflammatory  
16 Syndrome Induced by Adjuvants (“ASIA”) to refer to the spectrum of immune-  
17 mediated diseases triggered by an adjuvant stimulus contained in vaccines, such as  
18 aluminum. *See e.g.*, YEHUDA SHOENFELD ET AL, EDs., *VACCINES & AUTOIMMUNITY* 2  
19 (2015).

20 265. Indeed, even in animal studies, it has been revealed that aluminum  
21 adjuvants can induce autoimmune disease in tested animals. By way of example, in a  
22 series of studies conducted by Lluís Luján, DVM, Ph.D., and his colleagues, it was  
23 revealed that sheep injected with aluminum-containing adjuvants commonly come  
24 down with severe autoimmune diseases and other adverse reactions.

25 266. Specific to the Gardasil vaccines, which contain adjuvants, including,  
26 amorphous aluminum hydroxyphosphate sulfate (AAHS) and the previously  
27 undisclosed HPV L1 gene DNA fragments, a number of mechanisms of action have  
28 been outlined (as discussed *infra*) as to how Gardasil induces autoimmune disease in

1 select patients.

2 267. Given the number of HPV strains that exist, a great part of the human  
3 population has HPV, however, HPV by itself is generally not immunogenic, and  
4 generally does not evoke immune responses. Indeed, HPV shares a high number of  
5 peptide sequences with human proteins, so that the human immune system generally  
6 does not react against HPV in order to not harm self-proteins. Immunotolerance thus  
7 generally blocks reactions against HPV in order to avoid autoimmune attacks against  
8 the human proteins.

9 268. To induce anti-HPV immune reactions, Merck added various adjuvants,  
10 including amorphous aluminum hydroxyphosphate sulfate (AAHS), to the Gardasil  
11 vaccine. Adjuvants, such as aluminum, are inflammatory substances that hyperactivate  
12 the immune system. Adjuvants are thus the “secret sauce” used by Merck to  
13 hyperactivate the immune system and make HPV immunogenic.

14 269. While adjuvants are added with the intent of destroying the HPV virus,  
15 they also can have the unintended result of rendering the immune system “blind” and  
16 unable to distinguish human proteins from HPV proteins – accordingly, human proteins  
17 that share peptide sequences with HPV are at risk of also being attacked by the vaccine.

18 270. While Gardasil causes immune hyperactivation and production of anti-  
19 HPV antibodies to fend off certain strains of the HPV virus, it can also result in the  
20 immune system losing its ability to differentiate human proteins from foreign proteins,  
21 causing the immune system to attack the body’s own proteins and organs. Because of  
22 the massive peptide commonality between HPV and human proteins, the indiscriminate  
23 attack triggered by the Gardasil adjuvants will cause massive cross-reactions and  
24 dangerous attacks against human proteins, leading to a number of autoimmune diseases  
25 manifested throughout the different organs of the body. This process is sometimes  
26 referred to as “molecular mimicry.”

27 271. In addition to “molecular mimicry,” other mechanisms of action that  
28 explain how Gardasil can induce autoimmune disease are “epitope spreading,” whereby

1 invading Gardasil antigens, including the toxic aluminum adjuvant, accelerate  
2 autoimmune process by location activation of antigen presenting cells and “bystander  
3 activation,” wherein antigens and the aluminum adjuvants in the Gardasil vaccine  
4 activate pre-primed autoreactive T cells, which can initiate autoimmune disease  
5 (bystander activation of autoreactive immune T cells), or where virus-specific T cells  
6 initiate bystander activation resulting in the immune system killing uninfected and  
7 unintended neighboring cells.

8         272. Relevant to the injuries at issue in this case, when a person is lying down,  
9 approximately one-quarter of their blood volume resides in the chest area. When the  
10 person stands up, a significant amount of that blood shifts to the lower extremities.  
11 This causes impaired return of blood flow to the heart which also reduces blood  
12 pressure. In healthy individuals, the autonomic nervous system adjusts the heartrate to  
13 counteract this effect and the hemodynamic changes are negligible. However, in  
14 individuals (such as Plaintiff) who are now suffering from dysautonomia or autonomic  
15 ailments, such as POTS or OI, the body’s ability to adjust the heartrate and compensate  
16 for the blood flow is corrupted resulting in a host of wide ranging symptoms, including  
17 but not limited to, dizziness, lightheadedness, vertigo, woozy sensation, chronic  
18 headaches, vision issues due to the loss of blood flow to the brain, light and sound  
19 sensitivity, loss of consciousness, shortness of breath, chest pain, gastrointestinal  
20 issues, body pains, insomnia, and confusion and/or difficulty sleeping. In certain cases  
21 of POTS, patients will also be diagnosed with other medical conditions, including but  
22 not limited to, chronic fatigue syndrome and fibromyalgia.

23         273. Medical research has determined that certain dysautonomia diseases such  
24 as POTS and OI have an autoimmune etiology. Norepinephrine, a key neurotransmitter  
25 of the sympathetic (“fight or flight”) system, exerts its mechanism of action by binding  
26 to receptors located in the smooth muscle of the blood vessels and various organs,  
27 including the heart. These receptors include alpha-1, alpha-2, beta-1, beta-2 and beta-3  
28 receptors and, as a group, are generally known as the adrenergic receptors. The

1 adrenergic receptors, and other receptors, including but not limited to, the ganglionic  
2 and muscarinic acetylcholine receptors are believed to be affected in certain cases of  
3 POTS and OI. *See e.g.*, Hongliang Li et al., *Autoimmune Basis for Postural*  
4 *Tachycardia Syndrome*, 3 J. AMERICAN HEART ASSOC. e000755 (2014); Artur  
5 Fedorowski et al., *Antiadrenergic Autoimmunity in Postural Tachycardia Syndrome*, 19  
6 EUROPACE 1211 (2017); Mohammed Ruzieh et al., *The Role of Autoantibodies in the*  
7 *Syndromes of Orthostatic Intolerance: A Systematic Review*, 51 SCANDINAVIAN  
8 CARDIOVASCULAR J. 243 (2017); Shu-ichi Ikeda et al., *Autoantibodies Against*  
9 *Autonomic Nerve Receptors in Adolescent Japanese Girls after Immunization with*  
10 *Human Papillomavirus Vaccine*, 2 ANNALS OF ARTHRITIS AND CLINICAL  
11 RHEUMATOLOGY 1014 (2019); William T. Gunning, *Postural Orthostatic Tachycardia*  
12 *Syndrome is Associated With Elevated G-Protein Coupled Receptor Autoantibodies*, 8  
13 J. AMERICAN HEART ASSOC. e013602 (2019).

14 274. A variety of published medical journal articles have discussed the  
15 association between Gardasil and a myriad of serious injuries and have reported on  
16 patients developing POTS, OI, fibromyalgia and other symptoms of autonomic  
17 impairment following Gardasil vaccination. *See* Svetlana Blitshetyn, *Postural*  
18 *Tachycardia Syndrome After Vaccination with Gardasil*, 17 EUROPEAN J. OF  
19 NEUROLOGY e52 (2010); Svetlana Blitshetyn, *Postural Tachycardia Syndrome*  
20 *Following Human Papillomavirus Vaccination*, 21 EUROPEAN J. OF NEUROLOGY 135  
21 (2014); Tomomi Kinoshita et al., *Peripheral Sympathetic Nerve Dysfunction in*  
22 *Adolescent Japanese Girls Following Immunization With Human Papillomavirus*  
23 *Vaccine*, 53 INTERNAL MEDICINE 2185 (2014); Louise S. Brinith et al., *Orthostatic*  
24 *Intolerance and Postural Tachycardia Syndrome As Suspected Adverse Effects of*  
25 *Vaccination Against Human Papilloma Virus*, 33 VACCINE 2602 (2015); Manuel  
26 Martinez-Lavin et al., *HPV Vaccination Syndrome. A Questionnaire Based Study*, 34 J.  
27 CLINICAL RHEUMATOLOGY 1981 (2015); Louise S. Brinith et al., *Is Chronic Fatigue*  
28 *Syndrome/Myalgic Encephalomyelitis a Relevant Diagnosis in Patients with Suspected*

1 *Side Effects to Human Papilloma Virus Vaccine*, 1 INT. J. OF VACCINE & VACCINATION  
2 3 (2015); Jill R. Schofield et al., *Autoimmunity, Autonomic Neuropathy, and HPV*  
3 *Vaccination, A Vulnerable Subpopulation*, CLINICAL PEDIATRICS (2017); Rebecca E.  
4 Chandler et al., *Current Safety Concerns With Human Papillomavirus Vaccine: A*  
5 *Cluster Analysis of Reports in Vigibase*, 40 DRUG SAFETY 81 (2017); Svetlana  
6 Blitshetyn et al., *Autonomic Dysfunction and HPV Immunization An Overview*,  
7 IMMUNOLOGIC RESEARCH (2018); and Svetlana Blitshetyn, *Human Papilloma Virus*  
8 *(HPV) Vaccine Safety Concerning POTS, CRPS and Related Conditions*, CLINICAL  
9 AUTONOMIC RESEARCH (2019).

10 275. In a 2017 review, Drs. Tom Jefferson and Lars Jørgensen criticized the  
11 European Medicines Agency (“EMA”) for turning a blind eye to the debilitating  
12 autoimmune injuries, including CRPS and POTS that young women had suffered  
13 following vaccination with HPV vaccine. Tom Jefferson et al., *Human Papillomavirus*  
14 *Vaccines, Complex Regional Pain Syndrome, Postural Orthostatic Tachycardia*  
15 *Syndrome, and Autonomic Dysfunction – A Review of the Regulatory Evidence from the*  
16 *European Medicines Agency*, 3 INDIAN J. OF MED. ETHICS 30 (Jan. – March 2017).

17 276. In a separate article, the same authors describe their process for extracting  
18 data from not only peer-reviewed journal publications, but also unpublished data from  
19 pharmaceutical company clinical study reports and trial register entries from  
20 ClinicalTrials.gov, under the assumption that “more than half of all studies are never  
21 published, and the published studies’ intervention effects are often exaggerated in  
22 comparison to the unpublished studies. This introduces reporting bias that undermines  
23 the validity of systematic reviews. To address reporting bias in systematic reviews, it is  
24 necessary to use industry and regulatory trial registers and trial data—in particular, the  
25 drug manufacturers’ complete study programs.” They found that 88 percent of industry  
26 studies were solely industry funded and found serious deficiencies and variability in the  
27 availability of HPV vaccine study data. For example, only half of the completed  
28 studies listed on ClinicalTrials.gov posted their results. The clinical study reports the

1 authors obtained confirmed that the amount of information and data are vastly greater  
2 than that in journal publications. When the authors compared the data the EMA used  
3 (which was provided by GlaxoSmithKline and Merck Sharp and Dohme) to conduct  
4 their review of the relationship between HPV vaccination and both POTS and CRPS,  
5 the authors found that only 48 percent of the manufacturers' data were reported.  
6 According to the authors, "we find this very disturbing." Lars Jørgensen et al., *Index of*  
7 *the Human Papillomavirus (HPV) Vaccine Industry Clinical Study Programmes and*  
8 *Non-Industry Funded Studies: A Necessary Basis to Address Reporting Bias in a*  
9 *Systematic Review*, 7 SYSTEMATIC REVIEW 8 (2018).

10 277. Likewise, in a recently released February 2020 peer-reviewed study,  
11 researchers who analyzed the available clinical trial data for all HPV vaccines, which  
12 include the Gardasil vaccines and another HPV vaccine currently only available in  
13 Europe, concluded that "HPV vaccines increased serious nervous disorders." Lars  
14 Jørgensen et al., *Benefits and Harms of the Human Papillomavirus (HPV) Vaccines:*  
15 *Systemic Review with Meta-Analyses of Trial Data from Clinical Study Reports*, 9  
16 SYSTEMATIC REVIEWS 43 (February 2020).

17 278. In addition, Jørgensen and his co-authors observed that, in reanalyzing the  
18 association between HPV vaccines and one specific autoimmune disease, POTS, the  
19 HPV vaccines were associated with a nearly two-fold increased risk of POTS. *Id.*

20 279. Jørgensen and his co-authors also noted many of the same shortcomings  
21 associated with the Gardasil clinical trials as have already been discussed in this  
22 Complaint, including for example, the fact that no true placebo was utilized by Merck  
23 as a comparator (i.e., the comparator/control used by Merck in the Gardasil clinical  
24 trials contained aluminum adjuvant). The researchers noted that "[t]he use of active  
25 comparators may have underestimated harms related to HPV vaccines," and that "[t]he  
26 degree of harms might therefore be higher in clinical practice than in the trials." *Id.*

27 280. Jørgensen and his co-authors also noted that the clinical trials revealed that  
28 Gardasil 9 induced more harms than Gardasil, which could be explained by the fact that

1 Gardasil 9 contains more of the AAHS aluminum adjuvant (500 micrograms of AAHS  
2 in Gardasil-9 vs. 225 micrograms of AAHS in Gardasil), and this dose-response  
3 relationship further corroborates the plausible claim that the AAHS aluminum adjuvant  
4 is a culprit in causing adverse events. *Id.*

5 281. Other researchers, including Tomljenovic and Shaw, who have closely  
6 looked into Gardasil, have opined that risks from the Gardasil vaccine seem to  
7 significantly outweigh the as yet unproven long-term benefits. In their view,  
8 vaccination is unjustified if the vaccine carries any substantial risk, let alone a risk of  
9 death, because healthy teenagers face an almost zero percent risk of death from cervical  
10 cancer.

11 **K. Merck has Concealed the Fact that Gardasil Increases the Risk of**  
12 **Fertility Problems**

13 282. Merck has never tested the impact of the Gardasil vaccines on human  
14 fertility.

15 283. Nevertheless, study volunteers reported devastating impacts on human  
16 fertility during combined trials, offering substantial evidence that the vaccine may be  
17 causing widespread impacts on human fertility, including increases in miscarriage, birth  
18 defects, premature ovarian failure and premature menopause in girls and young women.

19 284. One of the serious adverse events now emerging in vaccinated girls,  
20 including teens, is premature ovarian failure. *See, e.g.,* D. T. Little and H. R. Ward,  
21 *Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus*  
22 *Vaccination: A Case Series Seen in General Practice*, JOURNAL OF INVESTIGATIVE  
23 MEDICINE HIGH IMPACT, Case Reports 1-12 (Oct.-Dec. 2014); D. T. Little and H. R.  
24 Ward, *Premature ovarian failure 3 years after menarche in a 16-year-old girl*  
25 *following human papillomavirus vaccination*, BMJ CASE REPORTS (September 30,  
26 2012).

27 285. Premature ovarian failure can occur after aluminum destroys the  
28 maturation process of the eggs in the ovaries.

1 286. Fertility has plummeted among American women following the 2006 mass  
 2 introduction of the Gardasil vaccine. This is most evident in teen pregnancy statistics  
 3 where numbers have more than halved since 2007.


4 287. The total fertility rate for the United States in 2017 continued to dip below  
 5 what is needed for the population to replace itself, according to a report by the National  
 6 Center of Health Statistics issued in January 2019, and the rate for women 15 to 44 fell  
 7 another 2 percent between 2017 and 2018.

8 **L. There were an Increased Number of Deaths in the Gardasil Studies**

9 288. Merck’s own preliminary studies predicted that Gardasil would kill and  
 10 injure far more Americans than the HPV virus, prior to the introduction of the vaccine.

11 289. The average death rate in young women in the U.S. general population is  
 12 4.37 per 10,000. *See* Brady E. Hamilton et al., “Births: Provisional Data for 2016,”  
 13 *Vital Statistics Rapid Release, Report No. 002*, June 2017.

14 290. The Gardasil pooled group had a death rate of 8.5 per 10,000, or almost  
 15 double the background rate in the U.S.



16  
 17  
 18  
 19  
 20  
 21  
 22  
 23 Background CDC rate 4.37 source: National Vital Statistics Report Vol. 53 2002 page 24.<sup>37</sup>  
 Gardasil rate 8.5: 10/11,778. AAHS control rate 7.2: 7/9,680<sup>38</sup>  
 Cervical cancer mortality: 2.3 per 100,000 source: National Cancer Institute SEER Cancer Statistics Review 2015<sup>39</sup>

24  
 25  
 26 291. When Merck added in deaths from belated clinical trials, the death rate  
 27 jumped to 13.3 per 10,000 (21 deaths out of 15,706).

28 292. Merck dismissed all deaths as coincidences.

293. The total number of deaths was 21 in the HPV vaccine group and 19 in the

1 comparator (AAHS) groups.

2 294. The death rate among vaccine recipients was 13.3 per 10,000, or 133 per  
3 100,000 (21/15,706).

4 295. To put this in perspective, the death rate from cervical cancer in the United  
5 States is 2.3 per 100,000 women. This means that, according to Merck's own data, a  
6 girl is 58 times more likely to die from Gardasil than from cervical cancer.

7 **M. Post-Marketing Injuries -- The Raft of Injuries Seen in Merck's**  
8 **Clinical Trials Has Now Become A Population-Wide Chronic**  
9 **Disease Epidemic**

10 296. By 2010, reports coming in from all over the world linked the Gardasil  
11 vaccine to bizarre and troubling symptoms.

12 297. Many Gardasil survivors will have lifelong handicaps.

13 298. The severe adverse events from the Gardasil vaccination, seen since its  
14 widespread distribution, are similar to those injuries that Merck covered up during its  
15 clinical trials. They include autoimmune diseases, suicides, deaths, premature ovarian  
16 failures, reproductive problems, infertility, cervical cancer, sudden collapse, seizures,  
17 multiple sclerosis, strokes, heart palpitations, chronic muscle pain, complex regional  
18 pain syndrome, and weakness.

19 299. Other frequently reported injuries include disturbances of consciousness;  
20 systemic pain including headache, myalgia, arthralgia, back pain and other pain; motor  
21 dysfunction, such as paralysis, muscular weightiness, and involuntary movements;  
22 numbness, and sensory disturbances; autonomic symptoms including hypotension,  
23 tachycardia, nausea, vomiting, and diarrhea; respiratory dysfunction, including  
24 dyspnea, and asthma; endocrine disorders, such as menstrual disorder and  
25 hypermenorrhea; and lastly, hypersensitivity to light, heart palpitations, migraine  
26 headaches, dizziness, cognitive deficits, personality changes, vision loss, joint aches,  
27 headaches, brain inflammation, chronic fatigue, death, and severe juvenile rheumatoid  
28 arthritis.

1 300. The data show that Gardasil is yielding far more reports of adverse events  
2 than any other vaccine. For example, Gardasil had 8.5 times more emergency room  
3 visits, 12.5 times more hospitalizations, 10 times more life-threatening events, and 26.5  
4 more disabilities than Menactra, another vaccine with an extremely high-risk profile.

5 301. As of December 2019, there have been more than 64,000 Gardasil adverse  
6 events reported to the FDA's Vaccine Adverse Event Reporting System ("VAERS")  
7 since 2006.

8 302. Moreover, studies have shown that only approximately 1 percent of  
9 adverse events are actually reported to FDA's voluntary reporting systems, thus, the  
10 true number of Gardasil adverse events in the United States may be as high as 6.4  
11 million incidents.

12 303. The Vaccine Injury Compensation Program has paid out millions of dollars  
13 in damages for Gardasil-induced injuries and deaths.

14 304. The adverse events also include deaths. Parents, doctors, and scientists  
15 have reported hundreds of deaths from the Gardasil vaccine, post-marketing.

16 305. In order to conceal Gardasil's link to the deaths of teenagers, Merck has  
17 submitted fraudulent reports to VAERS, and posts fraudulent and misleading  
18 statements on its Worldwide Adverse Experience System.

19 306. For example, Merck attributed the death of a young woman from  
20 Maryland, Christina Tarsell, to a viral infection. Following years of litigation, a court  
21 determined that Gardasil caused Christina's death. There was no evidence of viral  
22 infection. Merck invented this story to deceive the public about Gardasil's safety.

23 307. Merck submitted fraudulent information about Christina Tarsell's death to  
24 its Worldwide Adverse Experience System and lied to the FDA through the VAERS  
25 system. Merck claimed that Christina's gynecologist had told the company that her  
26 death was due to viral infection. Christina's gynecologist denied that she had ever given  
27 this information to Merck. To this day, Merck has refused to change its false entry on  
28 its own reporting system.

1                   **N. The Gardasil Vaccines’ Harms Are Not Limited to the United**  
2                   **States, Rather the Vaccines Have Injured Patients All Over the**  
3                   **World**

4                   308. Gardasil is used widely in the international market. Widespread global  
5 experience has likewise confirmed that the vaccine causes serious adverse events with  
6 minimal proven benefit.

7                   309. According to the World Health Organization’s Adverse Event Databases,  
8 there have been more than 100,000 serious adverse events associated with Gardasil,  
9 outside the Americas. *See* WHO Vigibase database, keyword Gardasil:  
10 <http://www.vigiaccess.org>.

11                                   **i. In Light of Gardasil’s Serious and Debilitating Adverse**  
12                                   **Events, the Japanese Government Rescinded Its**  
13                                   **Recommendation that Girls Receive Gardasil**

14                   310. In Japan, a country with a robust history of relative honesty about vaccine  
15 side effects, the cascade of Gardasil injuries became a public scandal.

16                   311. Japan’s health ministry discovered adverse events reported after Gardasil  
17 were many times higher than other vaccines on the recommended schedule. These  
18 included seizures, severe headaches, partial paralysis, and complex regional pain  
19 syndrome. *See* Hirokuni Beppu et al., *Lessons Learnt in Japan From Adverse*  
20 *Reactions to the HPV Vaccine: A Medical Ethics Perspective*, 2 INDIAN J MED ETHICS  
21 82 (April-June 2017).

22                   312. Japanese researchers found that the adverse events rate of the HPV vaccine  
23 was as high as 9 percent, and that pregnant women injected with the vaccine aborted or  
24 miscarried 30 percent of their babies. *See* Ministry of Health, Labour and Welfare,  
25 Transcript “The Public Hearing on Adverse Events following HPV vaccine in Japan,”  
26 February 26, 2014.

27                   313. The injuries caused the Japanese government to rescind its  
28 recommendation that girls receive the HPV vaccine.

                  314. Japan withdrew its recommendation for Gardasil three months after it had

1 added the vaccine to the immunization schedule, due to “an undeniable causal  
2 relationship between persistent pain and the vaccination.”

3 315. Uptake rates for the vaccine in Japan are now under 1 percent, compared to  
4 53.7 percent fully vaccinated teenaged girls in the United States.

5 316. In late 2016 Japanese industry watchdog, MedWatcher Japan issued a  
6 scathing letter faulting the WHO for failing to acknowledge the growing body of  
7 scientific evidence demonstrating high risk of devastating side effects.

8 317. In 2015, the Japanese Association of Medical Sciences issued official  
9 guidelines for managing Gardasil injuries post-vaccination.

10 318. That same year, the Japanese Health Ministry published a list of medical  
11 institutions where staffs were especially trained to treat patients who had sustained  
12 Gardasil-induced injuries.

13 319. The Japanese government also launched a series of special clinics to  
14 evaluate and treat illnesses caused by the Gardasil vaccines.

15 320. The president of the Japanese Association of Medical Sciences stated that  
16 there was no proof that the vaccines prevent cancer.

17 321. These were developments that Merck was extremely anxious to suppress.

18 322. Merck hired the think tank, the Center for Strategic and International  
19 Studies (“CSIS”) and Professor Heidi Larson of the Vaccine Confidence Project in  
20 London, to assess the reasons for the Japanese situation. The overall conclusion was  
21 that the symptoms the girls were suffering from were psychogenic in nature and were a  
22 result of rumors spread online. In essence, Merck blamed the victims for the Gardasil-  
23 induced adverse events in Japan.

24 **ii. Denmark Has Opened Specialized Clinics Specifically**  
25 **Focused on Treating Gardasil-Induced Injuries, Including**  
26 **Gardasil-Induced Autoimmune Diseases**

27 323. In March 2015, Denmark announced the opening of five new “HPV  
28 clinics” to treat children injured by Gardasil vaccines. Over 1,300 cases flooded the

1 HPV clinics shortly after opening. *See* Zosia Chustecka, *Chronic Symptoms After HPV*  
2 *Vaccination: Danes Start Study*, MEDSCAPE (November 13, 2015).

3 **iii. Gardasil-Induced Adverse Events Caused the Government**  
4 **in Colombia to Conclude that Gardasil Would No Longer**  
5 **Be Mandatory**

6 324. In Colombia, more than 800 girls in the town of El Carmen de Bolivar  
7 reported reactions ranging from fainting to dizziness to paralysis in March of 2014,  
8 following vaccination with Gardasil.

9 325. With protests erupting across the country, the Colombian attorney general  
10 asked the Constitutional Court to rule on a lower court ruling on the outcome of a case  
11 of an injured girl.

12 326. In 2017, in response to an unresolved case, Colombia's constitutional  
13 court, ruled that the Colombian government could not infringe on the bodily integrity of  
14 its citizens. This decision meant that the government could not require the HPV vaccine  
15 to be mandatory.

16 **iv. India Halted Gardasil Trials and Accused Merck of**  
17 **Corruption After the Death of Several Young Girls Who**  
18 **were Participants in the Trial**

19 327. Seven girls died in the Gardasil trials in India coordinated by Merck and  
20 the Gates Foundation. A report by the Indian Parliament accused the Gates Foundation  
21 and Merck of conducting “a well-planned scheme to commercially exploit” the nation's  
22 poverty and powerlessness and lack of education in rural India in order to push  
23 Gardasil. *See* 72<sup>nd</sup> Report on the *Alleged Irregularities in the Conduct of Studies Using*  
24 *Human Papilloma Virus (HPV) Vaccine by Programme for Appropriate Technology in*  
*Health (PATH) in India* (August 2013).

25 328. The report alleges that Merck (through PATH, to whom it supplied  
26 vaccines) and the Gates Foundation resorted to subterfuge that jeopardized the health  
27 and well-being of thousands of vulnerable Indian children. The parliamentary report  
28 makes clear that the clinical trials could not have occurred without Merck corrupting

1 India's leading health organizations. *Id.*

2 329. The Report accused PATH, which was in collaboration with Merck, of  
3 lying to illiterate tribal girls to obtain informed consent, widespread forging of consent  
4 forms by Merck operatives, offering financial inducements to participate, and providing  
5 grossly inadequate information about potential risks. *Id.*

6 330. Many of the participants suffered adverse events including loss of  
7 menstrual cycles and psychological changes like depression and anxiety. According to  
8 the report: PATH's "sole aim has to been to promote the commercial interests of HPV  
9 vaccine manufacturers, who would have reaped a windfall of profits had they been  
10 successful in getting the HPV vaccine included in the universal immunization program  
11 of the country... This [conduct] is a clear-cut violation of the human rights of these girls  
12 and adolescents." *Id.*

13 331. A 2013 article in the *South Asian Journal of Cancer* concludes that the  
14 HPV vaccine program is unjustifiable. "It would be far more productive to understand  
15 and strengthen the reasons behind the trend of decreasing cervical cancer rates than to  
16 expose an entire population to an uncertain intervention that has not been proven to  
17 prevent a single cervical cancer or cervical cancer death to date." *See Sudeep Gupta, Is*  
18 *Human Papillomavirus Vaccination Likely to be a Useful Strategy in India?* 2 SOUTH  
19 ASIAN J CANCER 194 (October-December 2014).

20 332. The article goes on to say: "A healthy 16-year-old is at zero immediate risk  
21 of dying from cervical cancer, but is faced with a small, but real risk of death or serious  
22 disability from a vaccine that has yet to prevent a single case of cervical cancer... There  
23 is a genuine cause for concern regarding mass vaccination in this country." *Id.*

24 333. In April 2017, the Indian government blocked the Gates Foundation from  
25 further funding of the Public Health Foundation of India and other non-governmental  
26 organizations, effectively barring them from influencing India's national vaccine  
27 program. *See Nida Najar, India's Ban on Foreign Money for Health Group Hits Gates*  
28 *Foundation*, THE NEW YORK TIMES, April 20, 2017.

**O. Merck’s Fraud Has Paid Off Handsomely Resulting in Over \$3 Billion in Gardasil Sales Annually**

334. Merck’s corruption and fraud in researching, testing, labeling, and promoting Gardasil have paid off handsomely.

335. Presently, two doses of Gardasil 9 typically cost about \$450, plus the cost of two office visits.

336. By comparison, the cost of the DTaP vaccine is about \$25 per dose.

337. The HPV vaccine is the most expensive vaccine on the market.

338. Since approximately 1 in 42,000 American women die of cervical cancer annually, the cost of avoiding a single death is over \$18 million, assuming the Gardasil vaccine is 100 percent effective.

339. In 2018, the Gardasil vaccines made \$2.2 billion for Merck in the U.S. alone.

340. In 2019, Merck made \$3.7 billion in worldwide revenues from the Gardasil vaccines.

341. Gardasil is Merck’s most lucrative vaccine and its third-highest selling product.

342. Gardasil is crucial to Merck’s overall financial health. Merck identifies Gardasil as one of its “key products,” meaning that any change in Gardasil’s cash flow affects the corporation as a whole.

343. Merck’s 10-K financial reports note that, for example, the discovery of a previously unknown side effect, or the removal of Gardasil from the market, would hurt Merck’s bottom line.

\\  
\\  
\\  
\\

1           **III. Catherine Boss Sustained Autoimmune Disease, Postural Orthostatic**  
2           **Tachycardia Syndrome, Dysautonomia, and Other Serious Injuries, as**  
3           **A Result of Her Gardasil Injection(s)**

4           **A. Gardasil and Its Ingredients Caused Plaintiff’s Autoimmune**  
5           **Disease and Other Related Injuries and Has Resulted in Her**  
6           **Suffering from Severe, Debilitating, Disabling and Painful Chronic**  
7           **Injuries**

8           344. Plaintiff was 16 years old when she received her first dosage of Gardasil on  
9           December 12, 2016 at the recommendation of Michal Cidon, M.D. at AltaMed in Los  
10           Angeles, California.

11           345. The Gardasil vaccine was stated as a safe and effective vaccine for  
12           preventing cervical cancer. In light of the doctor’s recommendations, Plaintiff’s  
13           mother, Kathleen Boss, consented to Plaintiff being injected with the “cervical cancer  
14           vaccine,” Gardasil.

15           346. Additionally, Plaintiff’s mother relied upon Merck’s ubiquitous  
16           representations concerning the safety and efficacy of the Gardasil vaccine when she  
17           consented to her daughter’s Gardasil vaccination.

18           347. Prior to receiving her Gardasil injection(s), Plaintiff was in her normal state  
19           of health, physically active and attended school without difficulty.

20           348. Immediately following her first dosage of Gardasil, Plaintiff experienced  
21           significant fatigue, headache, shortness of breath, hypotension, abdominal pain, and  
22           near syncope. She fell asleep on the way home from the doctor’s office and slept until  
23           the next day, which was unusual for her.

24           349. On February 16, 2017, Plaintiff returned to AltaMed for a follow up  
25           appointment and “well child” visit with Matthew Keefer, M.D, who noted Plaintiff had  
26           continued episodes of syncope, as well as migraine with visual loss, vomiting, and  
27           intermittent panic attacks. During this visit, Plaintiff received her second dosage of  
28           Gardasil.

          350. On April 19, 2017, Plaintiff was evaluated by cardiologist Patrick Sullivan,  
          M.D. who noted frequent episodes of orthostatic lightheadedness, panic attacks,

1 fatigue, abdominal pains, and syncope occurring 1-2x per week. Dr. Sullivan  
2 performed orthostatic vital signs, and his assessment included “frequent dysautonomia  
3 symptoms, possibly postural orthostatic tachycardia syndrome.”

4 351. On May 12, 2017, Plaintiff was evaluated by gastroenterologist Yuhua  
5 Zheng, M.D., who noted abdominal pain since a young age, worsening over the past  
6 several months with nausea and sometimes vomiting, preventing her from attending  
7 school. Testing was done in July 2017, which showed that Plaintiff had mildly delayed  
8 gastric emptying consistent with gastroparesis. Additionally, Plaintiff had testing done  
9 in October 2017, which showed that Plaintiff had small intestinal bacterial overgrowth,  
10 a condition often seen in patients with gastroparesis.

11 352. On November 6, 2017, Plaintiff had a follow up appointment with Dr.  
12 Keefer, who noted continued dizziness and 15 episodes of syncope over the past month,  
13 difficulty sleeping, decreased appetite, severe menstrual cramps, lethargy, chills,  
14 shortness of breath and headache. Plaintiff received her third dosage of Gardasil at this  
15 visit.

16 353. As the months progressed, so did Plaintiff’s injuries. She was seen by  
17 multiple physicians and specialists for her complaints which now included: Dizziness,  
18 fatigue, lethargy, shakiness, frequent episodes of syncope, heart palpitations,  
19 lightheadedness, shortness of breath, headaches, migraines, nausea, vomiting, frequent  
20 viral and bacterial infections, abdominal pain, neck pain, back pain, pelvic pain, severe  
21 dysmenorrhea, anxiety, panic attacks, and insomnia.

22 354. As a result of her post-Gardasil symptoms, Plaintiff was unable to engage  
23 in normal activities that a normal young person would enjoy. She missed school  
24 frequently and has been forced to reduce her social and physical activities. Plaintiff  
25 had plans of a career managing exotic animals, but she has had to give up that dream,  
26 as such a career would be too dangerous given her physical condition.

27 355. Based upon her chronic and severe post-Gardasil symptoms, Plaintiff has  
28 been diagnosed with various medical conditions, including but not limited to, POTS,

1 dysautonomia, gastroparesis, migraines, syncope, pain disorder, and endometriosis.

2 356. As previously discussed, the medical literature has documented other  
3 patients who, like Plaintiff, have suffered serious autonomic dysfunctions, and who  
4 experienced the same side effects as those Plaintiff has suffered, and who were  
5 diagnosed with Gardasil-induced autonomic diseases. See E. Israeli et al., *Adjuvants*  
6 *and Autoimmunity*, 18 LUPUS 1217 (2009); Darja Kanduc, *Quantifying the Possible*  
7 *Cross-Reactivity Risk of an HPV16 Vaccine*, 8 JOURNAL OF EXPERIMENTAL  
8 THERAPEUTICS AND ONCOLOGY 65 (2009); Svetlana Blitshetyn, *Postural Tachycardia*  
9 *Syndrome After Vaccination with Gardasil*, 17 EUROPEAN J. OF NEUROLOGY e52  
10 (2010); Darja Kanduc, *Potential Cross-Reactivity Between HPV16 L1 Protein and*  
11 *Sudden Death Associated Antigens*, 9 JOURNAL OF EXPERIMENTAL THERAPEUTICS AND  
12 ONCOLOGY 159 (2011); Deirdre Little et al., *Premature ovarian failure 3 years after*  
13 *menarche in a 16-year-old girl following human papillomavirus vaccination*, BRIT.  
14 MED. J. CASE REPORTS (2012); Serena Colafrancesco et al., *Human Papilloma Virus*  
15 *Vaccine and Primary Ovarian Failure: Another Facet of the Autoimmune Inflammatory*  
16 *Syndrome Induced by Adjuvants*, 70 AM. J. REPRODUCTIVE IMMUNOLOGY 309 (2013);  
17 Maurizio Rinaldi et al., *Anti-Saccharomyces Cerevisiae Autoantibodies in Autoimmune*  
18 *Diseases: from Bread Baking to Autoimmunity*, 45 CLINICAL REVIEWS IN ALLERGY AND  
19 IMMUNOLOGY 152 (October 2013); Svetlana Blitshetyn, *Postural Tachycardia*  
20 *Syndrome Following Human Papillomavirus Vaccination*, 21 EUROPEAN J. OF  
21 NEUROLOGY 135 (2014); Tomomi Kinoshita et al., *Peripheral Sympathetic Nerve*  
22 *Dysfunction in Adolescent Japanese Girls Following Immunization With Human*  
23 *Papillomavirus Vaccine*, 53 INTERNAL MEDICINE 2185 (2014); Christopher A. Shaw et  
24 al., *Aluminum-Induced Entropy in Biological Systems: Implications for Neurological*  
25 *Disease*, JOURNAL OF TOXICOLOGY (2014); Louise S. Brinth et al., *Orthostatic*  
26 *Intolerance and Postural Tachycardia Syndrome As Suspected Adverse Effects of*  
27 *Vaccination Against Human Papilloma Virus*, 33 VACCINE 2602 (2015); Manuel  
28 Martinez-Lavin et al., *HPV Vaccination Syndrome. A Questionnaire Based Study*, 34 J.

1 CLINICAL RHEUMATOLOGY 1981 (2015); Louise S. Brinth et al., *Is Chronic Fatigue*  
 2 *Syndrome/Myalgic Encephalomyelitis a Relevant Diagnosis in Patients with Suspected*  
 3 *Side Effects to Human Papilloma Virus Vaccine*, 1 INT. J. OF VACCINE & VACCINATION  
 4 3 (2015); Jill R. Schofield et al., *Autoimmunity, Autonomic Neuropathy, and HPV*  
 5 *Vaccination, A Vulnerable Subpopulation*, CLINICAL PEDIATRICS (2017); Rebecca E.  
 6 Chandler et al., *Current Safety Concerns With Human Papillomavirus Vaccine: A*  
 7 *Cluster Analysis of Reports in VigiBase*, 40 DRUG SAFETY 81 (2017); Svetlana  
 8 Blitshetyn et al., *Autonomic Dysfunction and HPV Immunization An Overview*,  
 9 IMMUNOLOGIC RESEARCH (2018); and Svetlana Blitshetyn, *Human Papilloma Virus*  
 10 *(HPV) Vaccine Safety Concerning POTS, CRPS and Related Conditions*, CLINICAL  
 11 AUTONOMIC RESEARCH (2019); Lars Jørgensen et al., *Benefits and Harms of the Human*  
 12 *Papillomavirus (HPV) Vaccines: Systemic Review with Meta-Analyses of Trial Data*  
 13 *from Clinical Study Reports*, 9 SYSTEMATIC REVIEWS 43 (February 2020).

14 357. Plaintiff contends that her Gardasil injection(s) caused her to develop  
 15 serious and debilitating injuries, including but not limited to autonomic, neurological,  
 16 heterogenous autoimmune disease, POTS, dysautonomia, gastroparesis, migraines,  
 17 syncope, pain disorder, and endometriosis, as well as a constellation of adverse  
 18 symptoms, complications, injuries, and other adverse events, many of which are alleged  
 19 herein and all of which were caused by Gardasil or otherwise linked to her Gardasil-  
 20 induced autoimmune disorder.

21 **B. “It is Not Revolutions and Upheavals That Clear the Road to New**  
 22 **and Better Days, But Revelations, Lavishness and Torments of**  
 23 **Someone’s Soul, Inspired and Ablaze.” – Boris Pasternak, After the**  
 24 **Storm**

25 358. Pursuant to Section 300aa-11(a) of the National Vaccine Injury  
 26 Compensation Program: “No person may bring a civil action for damages ..... against a  
 27 vaccine administrator or manufacturer in a State or Federal court for damages arising  
 28 from a vaccine-related injury ... associated with the administration of a vaccine .....  
 unless a petition has been filed, in accordance with section 300aa-16 of this title, for

1 compensation under the Program for such injury ... and (I) the United States Court of  
2 Federal Claims has issued a judgment under section 300aa-12 of this title on such  
3 petition and (II) such person elects under section 300aa-21(a) to file such an action.”  
4 *See* 42 U.S.C. §§ 300aa-11(a)(2)(A).

5 359. Title 42, Section 300aa-16 (c) further states: “If a petition is filed under  
6 section 300aa-11 of this title for a vaccine-related injury or death, limitations of actions  
7 under State law shall be stayed with respect to a civil action brought for such injury or  
8 death for the period beginning on the date the Petition is filed and ending on the  
9 date...an election is made under section 300aa-21(a) of this title to file the civil action  
10 ...” *See* 42 U.S.C. §§ 300aa-16(c).

11 360. In full compliance with the aforementioned federal law, Plaintiff duly filed  
12 her petition with the U.S. Court of Federal Claims seeking compensation for her  
13 Gardasil vaccine-related injuries under the National Vaccine Injury Compensation  
14 Program. A judgement thereon was rendered on or about July 29, 2022, and Plaintiff  
15 duly filed her election to file a civil action.

16 361. Having complied with National Vaccine Injury Compensation Program  
17 administrative procedure and having duly filed her election to proceed with a civil  
18 action, Plaintiff hereby timely initiates the instant action against Merck, the  
19 manufacturer and promoter of the Gardasil vaccines which caused her debilitating  
20 injuries. Through this civil action, Plaintiff seeks to hold Merck accountable for its  
21 negligent, reckless, and fraudulent conduct and she seeks full compensation from  
22 Merck for the physical and emotional injuries and harms she sustained as a result of  
23 Gardasil.

24 **CAUSES OF ACTION**

25 **COUNT ONE**

26 **NEGLIGENCE**

27 362. Plaintiff incorporates by reference all other paragraphs of this Complaint as  
28 if fully set forth herein and further alleges:

1 363. Merck is the researcher, manufacturer, labeler, and promoter of the  
2 Gardasil and the subsequent Gardasil 9 vaccines.

3 364. Merck marketed Gardasil to patients, including teenagers such as Plaintiff  
4 and her medical providers.

5 365. Merck had a duty to exercise reasonable care in the research, manufacture,  
6 marketing, advertisement, supply, promotion, packaging, sale, and distribution of  
7 Gardasil, including the duty to take all reasonable steps necessary to research,  
8 manufacture, label, promote and/or sell a product that was not unreasonably dangerous  
9 to consumers, users, and other persons coming into contact with the product.

10 366. At all times relevant to this litigation, Merck had a duty to exercise  
11 reasonable care in the marketing, advertising, and sale of Gardasil. Merck's duty of  
12 care owed to consumers and the general public included providing accurate, true, and  
13 correct information concerning the efficacy and risks of Gardasil and appropriate,  
14 complete, and accurate warnings concerning the potential adverse effects of Gardasil  
15 and its various ingredients and adjuvants.

16 367. At all times relevant to this litigation, Merck knew or, in the exercise of  
17 reasonable care, should have known of the hazards and dangers of Gardasil and  
18 specifically, the serious, debilitating and potentially fatal adverse events associated with  
19 Gardasil, including but not limited to autoimmune diseases (including, but not limited  
20 to, POTS and OT), fibromyalgia, increased risk of cancer (including cervical cancer,  
21 which was the very cancer it was promoted as preventing), and death.

22 368. Accordingly, at all times relevant to this litigation, Merck knew or, in the  
23 exercise of reasonable care, should have known that use of Gardasil could cause  
24 Plaintiff's injuries and thus created a dangerous and unreasonable risk of injury to the  
25 users of these products, including Plaintiff.

26 369. Merck knew or, in the exercise of reasonable care, should have known that  
27 its negligently and poorly performed clinical trials and studies were insufficient to test  
28 the true long-term safety and efficacy of Gardasil.

1 370. Merck also knew, or, in the exercise of reasonable care, should have known  
2 that its targeted consumers and patients (who were pre-teen and teen children), the  
3 parents of these patients and the children's medical providers were unaware of the true  
4 risks and the magnitude of the risks associated with Gardasil and the disclosed and  
5 undisclosed ingredients of Gardasil.

6 371. As such, Merck breached its duty of reasonable care and failed to exercise  
7 ordinary care in the research, development, manufacturing, testing, marketing, supply,  
8 promotion, advertisement, packaging, labeling, sale, and distribution of Gardasil, in that  
9 Merck manufactured and produced a defective and ineffective vaccine, knew or had  
10 reason to know of the defects and inefficacies inherent in its products, knew or had  
11 reason to know that a patient's exposure to Gardasil created a significant risk of harm  
12 and unreasonably dangerous side effects, and failed to prevent or adequately warn of  
13 these defects, risks and injuries.

14 372. Merck failed to appropriately and adequately test the safety and efficacy of  
15 Gardasil and its individual ingredients and adjuvants.

16 373. Despite the ability and means to investigate, study, and test its products and  
17 to provide adequate warnings, Merck has failed to do so. Indeed, Merck has  
18 wrongfully concealed information and has further made false and/or misleading  
19 statements concerning the safety and efficacy of Gardasil.

20 374. Merck's negligence is outlined in detail in this Complaint and included,  
21 among other things:

- 22 a) Manufacturing, producing, promoting, creating, researching,  
23 labeling, selling, and/or distributing Gardasil without thorough and  
24 adequate pre-and post-market testing and studies;
- 25 b) Manufacturing, producing, promoting, researching, labeling, selling,  
26 and/or distributing Gardasil while negligently and intentionally  
27 concealing and failing to accurately and adequately disclose the  
28 results of the trials, tests, and studies of Gardasil, and, consequently,

1 the lack of efficacy and risk of serious harm associated with  
2 Gardasil;

3 c) Failing to undertake sufficient studies and conduct necessary tests to  
4 determine the safety of the ingredients and/or adjuvants contained  
5 within Gardasil, and the propensity of these ingredients to render  
6 Gardasil toxic, increase the toxicity of Gardasil, whether these  
7 ingredients are carcinogenic or associated with autoimmune diseases  
8 and other injures;

9 d) Negligently conducting its clinical trials so as to prevent the clinical  
10 trials from revealing the true risks, including but not limited to, long  
11 terms risks and risks of autoimmune diseases associated with  
12 Gardasil;

13 e) Negligently conducting its clinical trials so as to mask the true risks,  
14 including but not limited to, long terms risks and risks of  
15 autoimmune diseases and cancers associated with Gardasil;

16 f) Failing to test Gardasil against a true inert placebo and lying to the  
17 public that Gardasil was tested against a placebo, when in reality, all,  
18 or nearly all, studies used a toxic placebo that included the aluminum  
19 adjuvant AAHS;

20 g) Failing to have a sufficient number of studies for the targeted patient  
21 population which included pre-teen girls (and boys) between the  
22 ages of nine and 12;

23 h) Not using the commercial dosage (and instead using a lower dosage  
24 of the adjuvant and ingredients) in one of the key clinical trials used  
25 to obtain licensing for the commercial dosage of Gardasil;

26 i) Using restrictive exclusionary criteria in the clinical study patient  
27 population (including for example, the exclusion of anyone who had  
28 prior abnormal Pap tests, who had a history of immunological or

1 nervous system disorders, or was allergic to aluminum or other  
2 ingredients), but then not revealing or warning about these  
3 exclusionary criteria in the label and knowing that, for most of these  
4 ingredients and allergies, there are limited resources for the public to  
5 test for such allergies in advance of being vaccinated;

- 6 j) Negligently conducting its trials so as to create the illusion of  
7 efficacy when in reality the Gardasil Vaccines *have not* been shown  
8 to be effective against preventing cervical and anal cancer;
- 9 k) Failing to use reasonable and prudent care in the research,  
10 manufacture, labeling and development of Gardasil so as to avoid the  
11 risk of serious harm associated with the prevalent use of Gardasil;
- 12 l) Failing to provide adequate instructions, guidelines, warnings, and  
13 safety precautions to those persons who Merck could reasonably  
14 foresee would use and/or be exposed to Gardasil;
- 15 m) Failing to disclose to Plaintiff, her mother, her medical providers and  
16 to the general public that Gardasil is ineffective when used in  
17 patients who have previously been exposed to HPV, and also failing  
18 to disclose that Gardasil actually increases the risk of cervical  
19 cancer, including in any child or patient who has previously been  
20 exposed to HPV;
- 21 n) Failing to disclose to Plaintiff, her mother, her medical providers and  
22 to the general public that use of and exposure to Gardasil presents  
23 severe risks of cancer (including cervical cancer, the very cancer it is  
24 promoted as preventing), fertility problems, autoimmune diseases  
25 and other grave illnesses as alleged herein;
- 26 o) Failing to disclose to Plaintiff, her mother, her medical providers and  
27 to the general public that use of and exposure to Gardasil presents  
28 severe risks of triggering and increasing the risk of various

- 1 autoimmune diseases, including but not limited to POTS and OI;
- 2 p) Failing to disclose to Plaintiff, her mother, her medical providers and
- 3 to the general public that, contrary to Merck's promotion of the
- 4 vaccine, Gardasil has not been shown to be effective at preventing
- 5 cervical cancer and that the safest and most effective means of
- 6 monitoring and combating cervical cancer is regular testing,
- 7 including Pap tests;
- 8 q) Representing that Gardasil was safe and effective for its intended use
- 9 when, in fact, Merck knew or should have known the vaccine was
- 10 not safe and not effective for its intended use;
- 11 r) Falsely advertising, marketing, and recommending the use of
- 12 Gardasil, while concealing and failing to disclose or warn of the
- 13 dangers Merck knew to be associated with or caused by the use of
- 14 Gardasil;
- 15 s) Falsely promoting Gardasil as preventing cervical cancer when
- 16 Merck knows that it has not done any studies to demonstrate that
- 17 Gardasil prevents cervical cancer and, indeed, its clinical studies
- 18 revealed that Gardasil actually increases the risk of cervical cancer;
- 19 t) Engaging in false advertising and disease mongering by scaring
- 20 parents and children into believing that cervical and anal cancer is
- 21 far more prevalent than it really is; that all cervical and anal cancer
- 22 was linked to HPV; that Gardasil prevented cervical and anal cancer,
- 23 when in reality none of these representations were true as cervical
- 24 cancer rates were declining in the United States due to Pap testing
- 25 and Gardasil has not been shown to prevent against all strains of
- 26 HPV that are associated with cervical and anal cancer and, indeed, it
- 27 has never been shown to prevent cervical and anal cancer;
- 28 u) Failing to disclose all of the ingredients in Gardasil, including but

1 not limited to the fact that Gardasil contains dangerous HPV L1-  
2 DNA fragments and that these DNA fragments could act as a Toll-  
3 Like Receptor 9 (TLR9) agonist – further adjuvanting the vaccine  
4 and making it more potent and dangerous;

5 v) Declining to make any changes to Gardasil’s labeling or other  
6 promotional materials that would alert consumers and the general  
7 public of the true risks and defects of Gardasil;

8 w) Systemically suppressing or downplaying contrary evidence about  
9 the risks, incidence, and prevalence of the side effects of the Gardasil  
10 Vaccines by, inter alia, orchestrating the retraction of peer-reviewed  
11 and published studies and vilifying and attempting to ruin the careers  
12 of any scientists who openly question Gardasil’s safety and efficacy.

13 375. Merck knew and/or should have known that it was foreseeable that  
14 patients, such as Plaintiff, would suffer injuries as a result of Merck’s failure to  
15 exercise ordinary care in the manufacturing, marketing, labeling, distribution, and sale  
16 of Gardasil.

17 376. Plaintiff and, upon information and belief, her medical providers, did not  
18 know the true nature and extent of the injuries that could result from the intended use of  
19 and/or exposure to Gardasil or its adjuvants and ingredients.

20 377. Merck’s negligence was the proximate cause of the injuries, harm, and  
21 economic losses that Plaintiff suffered, and will continue to suffer, as described herein.

22 378. Had Merck not engaged in the negligent and fraudulent conduct alleged  
23 herein and/or had Merck via its labeling, advertisements, and promotions provided  
24 adequate and truthful warnings and properly disclosed and disseminated the true risks,  
25 limitations, and lack of efficacy associated with Gardasil to medical providers, patients  
26 and the public, then upon information and belief, Plaintiff’s medical providers would  
27 not have offered or recommended Gardasil to Plaintiff. Moreover, even if after  
28 Merck’s dissemination of truthful information concerning the true risks and efficacy

1 limitation of Gardasil, Plaintiff's medical providers had offered Gardasil, then upon  
2 information and belief, the providers would have heeded any warnings issued by Merck  
3 and relayed to Plaintiff the safety risks and efficacy limitations that Merck should have  
4 warned her about, but failed to do so. Had Plaintiff been informed of the true risks and  
5 efficacy limitation concerning Gardasil, either through her medical providers or  
6 through Merck's ubiquitous direct-to-consumer promotional marketing, on which  
7 Plaintiff and her mother relied, then Plaintiff's mother would never have consented to  
8 Plaintiff being injected with Gardasil.

9       379. As a proximate result of Merck's wrongful acts and omissions and its  
10 negligent and fraudulent testing, labeling, manufacturing, marketing and promotion of  
11 Gardasil, Plaintiff has suffered and continues to suffer severe and permanent physical  
12 injuries, and associated symptomology and has suffered severe and permanent  
13 emotional injuries, including pain and suffering. Plaintiff also has a substantial fear of  
14 suffering additional and ongoing harms, including but not limited to now being at an  
15 increased risk of cancer, and future symptoms and harms associated with her  
16 autoimmune disease and other injuries caused by Gardasil.

17       380. As a direct and proximate result of her Gardasil-induced injuries, Plaintiff  
18 has suffered and continues to suffer economic losses, including considerable financial  
19 expenses for medical care and treatment, and diminished income capacity, and she will  
20 continue to incur these losses and expenses in the future.

21       381. Merck's conduct, as described above, was aggravated, oppressive,  
22 fraudulent, and malicious. Merck regularly risks the lives of patients, including  
23 Plaintiff, with full knowledge of the limited efficacy of Gardasil and the severe and  
24 sometimes fatal dangers of Gardasil. Merck has made conscious decisions to not warn,  
25 or inform the unsuspecting public, including Plaintiff, her mother, and her medical  
26 providers. Merck's conduct, including its false promotion of Gardasil and its failure to  
27 issue appropriate warnings concerning the severe risks of Gardasil, created a substantial  
28 risk of significant harm to children and patients who were being injected with Gardasil,

1 and therefore warrants an award of punitive damages.

2 382. WHEREFORE, Plaintiff requests that the Court enter judgment in her  
3 favor for compensatory damages and punitive damages, together with interest, and  
4 costs herein incurred, and all such other and further relief as this Court deems just and  
5 proper. Plaintiff also demands a jury trial on the issues contained herein.

6 **COUNT TWO**  
7 **STRICT LIABILITY**  
8 **(FAILURE TO WARN)**

9 383. Plaintiff incorporates by reference all other paragraphs of this Complaint as  
10 if fully set forth herein, and further alleges:

11 384. Plaintiff brings this strict liability claim against Merck for failure to warn.

12 385. At all times relevant to this litigation, Merck engaged in the business of  
13 researching, testing, developing, manufacturing, marketing, selling, distributing, and  
14 promoting Gardasil, which is defective and unreasonably dangerous to consumers,  
15 including Plaintiff, because it does not contain adequate warnings or instructions  
16 concerning the dangerous characteristics of Gardasil and its ingredients and adjuvants.  
17 These actions were under the ultimate control and supervision of Merck.

18 386. Merck researched, developed, tested, manufactured, inspected, labeled,  
19 distributed, marketed, promoted, sold, and otherwise released into the stream of  
20 commerce Gardasil, and in the course of same, directly advertised or marketed the  
21 vaccine to consumers and end users, including Plaintiff, her mother, and her medical  
22 providers, and Merck therefore had a duty to warn of the risks associated with the  
23 reasonably foreseeable uses of Gardasil and a duty to instruct on the proper, safe use of  
24 these products.

25 387. At all times relevant to this litigation, Merck had a duty to properly  
26 research, test, manufacture, inspect, package, label, market, promote, sell, distribute,  
27 provide proper warnings, and take such steps as necessary to ensure that Gardasil did  
28 not cause users and consumers to suffer from unreasonable and dangerous risks. Merck

1 had a continuing duty to instruct on the proper, safe use of these products. Merck, as  
2 manufacturer, seller, or distributor of vaccines, is held to the knowledge of an expert in  
3 the field.

4 388. At the time of manufacture, Merck could have provided warnings or  
5 instructions regarding the full and complete risks of Gardasil because it knew or should  
6 have known of the unreasonable risks of harm associated with the use of and/or  
7 exposure to these products.

8 389. At all times relevant to this litigation, Merck failed to properly investigate,  
9 study, research, test, manufacture, label or promote Gardasil. Merck also failed to  
10 minimize the dangers to children, patients, and consumers of Gardasil products and to  
11 those who would foreseeably use or be harmed by Gardasil, including Plaintiff.

12 390. Despite the fact that Merck knew or should have known that Gardasil  
13 posed a grave and unreasonable risk of harm (including but not limited to increased risk  
14 of autoimmune disease, and the various other Gardasil induced injuries that Plaintiff  
15 has sustained), it failed to warn of the risks associated with Gardasil. The dangerous  
16 propensities of Gardasil and the carcinogenic characteristics and autoimmune-inducing  
17 characteristics of Gardasil, as described in this Complaint, were known to Merck, or  
18 scientifically knowable to Merck through appropriate research and testing by known  
19 methods, at the time it distributed, supplied, or sold Gardasil, and not known to end  
20 users and consumers, such as Plaintiff, her mother, and her medical providers.

21 391. Merck knew or should have known that Gardasil and its ingredients and  
22 adjuvants created significant risks of serious bodily harm to children and patients, as  
23 alleged herein, and Merck failed to adequately warn patients, parents, medical  
24 providers and reasonably foreseeable users of the risks and lack of efficacy of Gardasil.  
25 Merck has wrongfully concealed information concerning Gardasil's dangerous nature  
26 and lack of efficacy and has further made false and misleading statements concerning  
27 the safety and efficacy of Gardasil.

28 392. Plaintiff was injected with Gardasil in its intended or reasonably

1 foreseeable manner without knowledge of its unreasonable dangerous and inefficacious  
2 characteristics.

3 393. Plaintiff could not have reasonably discovered the defects and risks  
4 associated with Gardasil before or at the time of her injections. Plaintiff relied upon the  
5 skill, superior knowledge, and judgment of Merck.

6 394. Merck knew or should have known that the warnings disseminated with  
7 Gardasil were inadequate, and failed to communicate adequate information concerning  
8 the true risks and lack of efficacy of Gardasil and failed to communicate warnings and  
9 instructions that were appropriate and adequate to render the products safe for their  
10 ordinary, intended, and reasonably foreseeable uses, including injections in teenagers.

11 395. The information that Merck did provide or communicate failed to contain  
12 relevant warnings, hazards, and precautions that would have enabled patients, parents  
13 of patients and the medical providers of patients to properly utilize, recommend or  
14 consent to the utilization of Gardasil. Instead, Merck disseminated information that  
15 was inaccurate, false, and misleading and which failed to communicate accurately or  
16 adequately the lack of efficacy, comparative severity, duration, and extent of the  
17 serious risk of injuries associated Gardasil; continued to aggressively promote the  
18 efficacy and safety of its products, even after it knew or should have known of  
19 Gardasil's unreasonable risks and lack of efficacy; and concealed, downplayed, or  
20 otherwise suppressed, through aggressive marketing and promotion, any information or  
21 research about the risks, defects and dangers of Gardasil.

22 396. To this day, Merck has failed to adequately and accurately warn of the true  
23 risks of Plaintiff's injuries, including but not limited to, autoimmune diseases, including  
24 POTS and dysautonomia, associated with the use of and exposure to Gardasil, and has  
25 failed to warn of the additional risks that Plaintiff is now exposed to, including, but not  
26 limited to, the increased risk of cancer, and other potential side effects and ailments.

27 397. As a result of Merck's failure to warn and false promotion, Gardasil is and  
28 was defective and unreasonably dangerous when it left the possession and/or control of

1 Merck, was distributed by Merck, and used by Plaintiff.

2 398. Merck is liable to Plaintiff for injuries caused by its failure, as described  
3 above, to provide adequate warnings or other clinically relevant information and data  
4 regarding Gardasil, the lack of efficacy and serious risks associated with Gardasil and  
5 its ingredients and adjuvants.

6 399. The defects in Merck's Gardasil vaccine were substantial and contributing  
7 factors in causing Plaintiff's injuries, and, but for Merck's misconduct and omissions  
8 and Gardasil's defects, including its defective labeling and false promotion, Plaintiff  
9 would not have sustained her injuries which she has sustained to date, and would not  
10 have been exposed to the additional prospective risk and dangers that are associated  
11 with Gardasil.

12 400. Had Merck not engaged in the negligent and fraudulent conduct alleged  
13 herein and/or had Merck, via its labeling, advertisements, and promotions provided  
14 adequate and truthful warnings and properly disclosed and disseminated the true risks,  
15 limitations, and lack of efficacy associated with Gardasil to medical providers, patients  
16 and the public, then upon information and belief, Plaintiff's medical providers would  
17 not have offered or recommended Gardasil to Plaintiff. Moreover, even if after  
18 Merck's dissemination of truthful information concerning the true risks and efficacy  
19 limitation of Gardasil, Plaintiff's medical providers had offered Gardasil, then upon  
20 information and belief, the providers would have heeded any warnings issued by Merck  
21 and relayed to Plaintiff the safety risks and efficacy limitations that Merck should have  
22 warned her about, but failed to do so. Had Plaintiff been informed of the true risks and  
23 efficacy limitation concerning Gardasil, through her medical providers or through  
24 Merck's ubiquitous direct-to-consumer promotional marketing, on which she and her  
25 mother relied, then Plaintiff's mother would not have consented to Plaintiff being  
26 injected with Gardasil.

27 401. As a proximate result of Merck's wrongful acts and omissions and its  
28 negligent and fraudulent testing, labeling, manufacturing, and promotion of Gardasil,

1 Plaintiff has suffered and continues to suffer severe and permanent physical injuries,  
2 including, but not limited to, her autoimmune disease and associated symptomology  
3 and has suffered severe and permanent emotional injuries, including pain and suffering.  
4 Plaintiff also has a substantial fear of suffering additional and ongoing harms, including  
5 but not limited to now being at an increased risk of cancer, and future symptoms and  
6 harms associated with her autoimmune disease and other injuries caused by Gardasil.

7 402. As a direct and proximate result of her Gardasil-induced injuries, Plaintiff  
8 has suffered and continues to suffer economic losses, including considerable financial  
9 expenses for medical care and treatment, and diminished income capacity and she will  
10 continue to incur these losses and expenses in the future.

11 403. Merck's conduct, as described above, was oppressive, fraudulent, and  
12 malicious. Merck regularly risks the lives of teenagers, including Plaintiff, with full  
13 knowledge of the limited efficacy of Gardasil and the severe and sometimes fatal  
14 dangers of Gardasil. Merck has made conscious decisions to not warn or inform the  
15 unsuspecting public, including Plaintiff, her mother, and her medical providers.  
16 Merck's conduct, including its false promotion of Gardasil and its failure to issue  
17 appropriate warnings concerning the severe risks of Gardasil, created a substantial risk  
18 of significant harm to children, teenagers, and patients who were being injected with  
19 Gardasil, and therefore warrants an award of punitive damages.

20 404. WHEREFORE, Plaintiff requests that the Court enter judgment in her  
21 favor for all compensatory and punitive damages, together with interest, and costs  
22 herein incurred, and all such other and further relief as this Court deems just and  
23 proper. Plaintiff also demands a jury trial on the issues contained herein.

24 **COUNT THREE**

25 **STRICT LIABILITY**

26 **(MANUFACTURING DEFECT)**

27 405. Plaintiff incorporates by reference all other paragraphs of this Complaint as  
28 if fully set forth herein, and further alleges:

1 406. Plaintiff brings this strict liability claim against Merck for manufacturing  
2 defect.

3 407. At all times relevant to this litigation, Merck engaged in the business of  
4 researching, testing, developing, manufacturing, marketing, selling, distributing, and  
5 promoting Gardasil, which is defective and unreasonably dangerous to consumers,  
6 including Plaintiff, because of manufacturing defects, which patients, including  
7 Plaintiff, her mother, and her medical providers did not expect.

8 408. Upon information and belief, the Gardasil vaccines injected into Plaintiff  
9 were defective and unreasonably dangerous because they failed to comply with  
10 manufacturing specifications required by the governing manufacturing protocols and  
11 also required by the regulatory agencies, including but not limited to the FDA, by  
12 among other things, containing ingredients and toxins that were not disclosed in the  
13 FDA-approved specifications and/or otherwise not disclosed in the package insert.

14 409. Upon information and belief, and as way of example, the Gardasil injected  
15 into Plaintiff was defective and unreasonably dangerous because it failed to comply  
16 with the approved manufacturing specifications, by containing dangerous and  
17 undisclosed HPV L1-DNA fragments, and these DNA fragments could act as a Toll-  
18 Like Receptor 9 (TLR9) agonist, further adjuvanting the vaccine and making it more  
19 potent and dangerous than intended.

20 410. Upon information and belief, and as way of example, the Gardasil injected  
21 into Plaintiff was defective and unreasonably dangerous because it failed to comply  
22 with the approved manufacturing specifications, by containing dangerous and  
23 undisclosed ingredients and neurotoxins, including but not limited to,  
24 phenylmethylsulfonyl fluoride (PMSF), a toxic nerve agent that is not intended for  
25 human consumption or injections.

26 411. Plaintiff, her mother, and her medical providers could not reasonably have  
27 discovered the defects, including the manufacturing defects, and risks associated with  
28 Gardasil before or at the time of her injections. Plaintiff relied upon the skill, superior

1 knowledge, and judgment of Merck.

2 412. Merck is liable to Plaintiff for injuries caused as a result of its  
3 manufacturing defects.

4 413. The defects in Merck's Gardasil vaccine were substantial and contributing  
5 factors in causing Plaintiff's injuries, and, but for Merck's misconduct and omissions  
6 and Gardasil's defects, including but not limited to its manufacturing defects, Plaintiff  
7 would not have sustained the injuries he has sustained to date, and would not have been  
8 exposed to the additional prospective risk and dangers associated with Gardasil.

9 414. As a proximate result of Merck's wrongful acts and Gardasil's  
10 manufacturing defects, Plaintiff has suffered and continues to suffer severe and  
11 permanent physical injuries and associated symptomology and has suffered severe and  
12 permanent emotional injuries, including pain and suffering. Plaintiff also has a  
13 substantial fear of suffering additional and ongoing harms, including but not limited to  
14 now being at an increased risk of cancer, and future symptoms and harms associated  
15 with her autoimmune disease and other injuries caused by Gardasil.

16 415. As a direct and proximate result of her Gardasil-induced injuries, Plaintiff  
17 has suffered and continues to suffer economic losses, including considerable financial  
18 expenses for medical care and treatment, and diminished income capacity, and she will  
19 continue to incur these losses and expenses in the future.

20 416. Merck's conduct, as described above, was oppressive, fraudulent, and  
21 malicious. Merck regularly risks the lives of patients, including Plaintiff, with full  
22 knowledge of the limited efficacy of Gardasil and the severe and sometimes fatal  
23 dangers of Gardasil. Merck has made conscious decisions to not warn, or inform the  
24 unsuspecting public, including Plaintiff, her mother, and her medical providers.  
25 Merck's conduct, including its false promotion of Gardasil and its failure to issue  
26 appropriate warnings concerning the severe risks of Gardasil, created a substantial risk  
27 of significant harm to children and patients who were being injected with Gardasil, and  
28 therefore warrants an award of punitive damages.

1 417. WHEREFORE, Plaintiff requests that the Court enter judgment in her  
2 favor for compensatory and punitive damages, together with interest, and costs herein  
3 incurred, and all such other and further relief as this Court deems just and proper.  
4 Plaintiff also demands a jury trial on the issues contained herein.

5 **COUNT FOUR**

6 **BREACH OF EXPRESS WARRANTY**

7 418. Plaintiff incorporates by reference all other paragraphs of this Complaint as  
8 if fully set forth herein, and further alleges:

9 419. Merck engaged in the business of testing, researching, manufacturing,  
10 labeling, marketing, selling, distributing, and promoting Gardasil, which is defective  
11 and unreasonably dangerous to consumers, including Plaintiff.

12 420. At all times relevant to this litigation, Merck expressly represented and  
13 warranted through statements made in its Gardasil label, publications, television  
14 advertisements, billboards, print advertisements, online advertisements and website,  
15 and other written materials intended for consumers, patients, parents of minor-aged  
16 patients, medical providers and the general public, that Gardasil was safe and effective  
17 at preventing cancer. Merck advertised, labeled, marketed, and promoted Gardasil,  
18 representing the quality to consumers, patients, medical providers and the public in  
19 such a way as to induce their purchase or use, thereby making an express warranty that  
20 Gardasil would conform to the representations.

21 421. These express representations included incomplete warnings and  
22 instructions that purport, but fail, to include the complete array of risks associated with  
23 Gardasil. Merck knew and/or should have known that the risks expressly included in  
24 Gardasil's promotional material and labels did not and do not accurately or adequately  
25 set forth the risks of developing the serious injuries complained of herein.  
26 Nevertheless, Merck falsely and expressly represented that Gardasil was "safe" for use  
27 by individuals such as Plaintiff, and/or that Gardasil was "effective" in preventing  
28 cancer and that anyone who was vaccinated with Gardasil would be "one less" person

1 with cancer.

2 422. The representations about Gardasil, as set forth herein, contained or  
3 constituted affirmations of fact or promises made by the seller to the buyer, which  
4 related to the goods and became part of the basis of the bargain, creating an express  
5 warranty that the goods would conform to the representations.

6 423. Merck breached these warranties because, among other things, Gardasil is  
7 ineffective at preventing cancer, defective, dangerous, unfit for use, and is associated  
8 with a myriad of dangerous and undisclosed risks, including, but not limited to, the risk  
9 of autoimmune disease, including POTS, the risk of developing cervical cancer in  
10 women (even though Merck promoted it as preventing cervical cancer), and the risk of  
11 fertility problems for young girls. Specifically, Merck breached the warranties in the  
12 following ways:

13 a) Representing to patients and the medical community, including  
14 Plaintiff, her mother and/or her medical providers that Gardasil is  
15 effective in preventing cancer, including anal and cervical cancer,  
16 when Merck knew that contrary to these representations (i) no  
17 clinical studies were performed to test if Gardasil prevents cancer;  
18 (ii) the clinical studies confirmed that Gardasil is indeed ineffective  
19 when used in patients who have previously been exposed to HPV,  
20 and that Gardasil actually increases the risk of cancer in a patient  
21 who has been previously exposed to HPV; and (iii) there are safer  
22 and more effective methods of monitoring for and attempting to  
23 prevent cervical or anal cancer, including but not limited to regular  
24 testing, such as regular Pap smears for cervical cancer, and  
25 monitoring for anal cancer.

26 b) Representing to patients and the medical community, including  
27 Plaintiff, her mother, and her medical providers that Gardasil is safe,  
28 when in reality, Gardasil causes and presents serious risks of cancer,

1 autoimmune disease, including but not limited to POTS, and other  
2 grave illnesses as outlined herein;

3 c) Engaging in false advertising and disease mongering by scaring  
4 parents and teenagers into believing that cervical and anal cancer is  
5 far more prevalent than it really is; that all cervical and anal cancer  
6 was linked to HPV; that Gardasil prevented cervical cancer, when in  
7 reality none of these representations were true as cervical cancer  
8 rates were declining in the United States due to Pap testing and  
9 Gardasil has not been shown to prevent against all strains of HPV  
10 that are associated with cervical cancer and indeed it has never been  
11 shown to prevent cervical or anal cancer.

12 424. Merck had sole access to material facts concerning the nature of the risks  
13 and defects associated with Gardasil as expressly stated within its promotional material  
14 and labels, and Merck knew that patients and users such as Plaintiff could not have  
15 reasonably discovered the truth about the inefficacies and serious risks associated with  
16 Gardasil as alleged herein.

17 425. Plaintiff had no knowledge of the falsity or incompleteness of Merck's  
18 statements and representations concerning Gardasil.

19 426. Plaintiff was exposed to and relied upon the ubiquitous promotional  
20 material and representations Merck made in its direct-to-consumer advertisements and  
21 marketing materials concerning the safety and efficacy of Gardasil, including: that  
22 Gardasil prevents cervical and anal cancer and these cancers are prevalent (even though  
23 children rarely get cervical or anal cancer and Pap tests are the best frontline defense in  
24 detecting and fighting cervical cancer); that "good mothers" vaccinate their children  
25 and that Gardasil is perfectly safe. However, had Merck in these advertisements not  
26 engaged in disease mongering and deception, but instead had informed her the truth  
27 about the serious risks of Gardasil (as outlined in this Complaint) and its lack of  
28 efficacy, Plaintiff's mother would never have consented to Plaintiff being injected with

1 Gardasil, nor would Plaintiff's mother have consented to the Gardasil injection(s) had  
2 she been adequately informed about the questionable efficacy and serious risks  
3 associated with Gardasil.

4 427. As a proximate result of Merck's wrongful acts and breaches of warranties  
5 concerning the safety and efficacy of Gardasil, Plaintiff has suffered and continues to  
6 suffer severe and permanent physical injuries, and associated symptomology and has  
7 suffered severe and permanent emotional injuries, including pain and suffering.  
8 Plaintiff also has a substantial fear of suffering additional and ongoing harms, including  
9 but not limited to now being at an increased risk of cancer, and future symptoms and  
10 harms associated with her autoimmune disease and other injuries caused by Gardasil.

11 428. As a direct and proximate result of her Gardasil-induced injuries, Plaintiff  
12 has suffered and continues to suffer economic losses, including considerable financial  
13 expenses for medical care and treatment, and diminished income capacity and she will  
14 continue to incur these losses and expenses in the future.

15 429. Merck's conduct, as described above, was oppressive, fraudulent, and  
16 malicious. Merck regularly risks the lives of patients, including Plaintiff, with full  
17 knowledge of the limited efficacy of Gardasil and the severe and sometimes fatal  
18 dangers of Gardasil. Merck has made conscious decisions to not warn, or inform the  
19 unsuspecting public, including Plaintiff, her mother, and her medical providers.  
20 Merck's conduct, including its false promotion of Gardasil and its failure to issue  
21 appropriate warnings concerning the severe risks of Gardasil, created a substantial risk  
22 of significant harm to children and patients who were being injected with Gardasil, and  
23 therefore warrants an award of punitive damages.

24 430. WHEREFORE, Plaintiff requests that the Court enter judgment in her  
25 favor for compensatory and punitive damages, together with interest, and costs herein  
26 incurred, and all such other and further relief as this Court deems just and proper.  
27 Plaintiff also demands a jury trial on the issues contained herein.

28 **COUNT FIVE**

**COMMON LAW FRAUD**

1  
2 431. Plaintiff incorporates by reference all other paragraphs of this Complaint as  
3 if fully set forth herein, and further alleges:

4 432. Merck is the researcher, manufacturer, labeler, and promoter of Gardasil.

5 433. Merck marketed Gardasil to and for the benefit of patients, including  
6 teenagers such as Plaintiff, and her medical providers.

7 434. Merck had a duty to deal honestly and truthfully with regulators, patients,  
8 consumers and medical providers in its development, testing, marketing, promotion,  
9 and sale of Gardasil.

10 435. Merck’s duty of care owed to patients and medical providers included  
11 providing accurate, complete, true, and correct information concerning the efficacy and  
12 risks of Gardasil in its direct-to-consumer advertisements, promotional material, and  
13 labeling.

14 436. At all times relevant to this litigation, Merck knew or should have known  
15 of the hazards and dangers of Gardasil and specifically, the serious, debilitating and  
16 potentially fatal adverse events associated with Gardasil, including but not limited to  
17 autoimmune diseases, increased risk of cancer, and death.

18 437. At all times relevant to this litigation, Merck knew or should have known  
19 that its poorly implemented clinical trials and studies were insufficient to test the true  
20 long-term safety and efficacy of Gardasil.

21 438. At all times relevant to this litigation, Merck expressly represented through  
22 statements it made in its publications, ubiquitous television advertisements, billboards,  
23 print advertisements, online advertisements and website, and other written materials  
24 intended for consumers, patients, parents of minor-aged patients, medical providers and  
25 the general public, that Gardasil was safe and effective at preventing cancer.

26 439. These express representations included incomplete warnings and  
27 instructions that purport, but fail, to include the complete array of risks associated with  
28 Gardasil. By way of example Merck’s marketing material, including its “One Less”

1 television and print advertisement campaign (including but not limited to Gardasil  
2 posters in medical facilities and doctors' offices), which Plaintiff had been exposed to,  
3 stated that Gardasil was safe, that Gardasil was effective in preventing cancer, that  
4 Gardasil was a "cervical cancer vaccine," and that any young child or teenager who  
5 was vaccinated with Gardasil would lead to "one less" person with cervical or anal  
6 cancer. The only safety warnings Merck provided in these marketing materials was that  
7 a patient could get pain, swelling or redness at injection site, fever, and/or nausea.

8 440. The ubiquitous nature of these Gardasil commercials and the Gardasil  
9 marketing campaign gave the impression that cervical cancer was on the rise and more  
10 prevalent than it actually was, and that all good mothers vaccinate their children with  
11 the "cervical cancer vaccine."

12 441. Merck knew or should have known that the risks expressly included in  
13 Gardasil's promotional material and labels did not and do not accurately or adequately  
14 set forth the true and complete risks of developing the serious injuries that are  
15 associated with Gardasil, as previously alleged herein, and which include but are not  
16 limited to POTS, systemic adverse events, autoimmune disease, increased risk of  
17 cancer, and death.

18 442. The same promises of efficacy and limited and incomplete warnings Merck  
19 relayed in its direct-to-consumer advertising, were what Plaintiff's medical providers  
20 relayed to her when they recommended Gardasil – i.e., that if Plaintiff got vaccinated  
21 with Gardasil, it would prevent cancer, and the only risks associated with Gardasil are  
22 soreness, redness, and minor pain may develop.

23 443. Plaintiff had been exposed to Merck's marketing material concerning  
24 Gardasil, including the aforementioned "One Less" marketing campaign and other print  
25 advertisements and posters at doctors' offices, and the representations made by Merck  
26 therein that Gardasil is effective at preventing cervical and anal cancer, that Gardasil is  
27 safe and that its only side-effects are essentially minor injection site pain and swelling,  
28 and the possible onset of a fever or nausea. Prior to providing consent to inject

1 Plaintiff with the Gardasil vaccine, Plaintiff was never informed by Merck, or anyone  
2 else, that Gardasil is linked to a host of serious debilitating and chronic adverse events  
3 including, autoimmune diseases (including, but not limited to, POTS), increased risk of  
4 cancer, and death.

5 444. Prior to providing consent to inject Plaintiff with the Gardasil vaccine,  
6 Plaintiff was never informed by Merck, or anyone else, that Merck had not conducted  
7 the proper testing necessary to demonstrate the efficacy and full safety of Gardasil.

8 445. Prior to providing consent to inject Plaintiff with the Gardasil vaccine,  
9 Plaintiff was never informed by Merck, or anyone else, that Merck had, as alleged  
10 herein, manipulated its clinical studies to mask and conceal the adverse events  
11 associated with Gardasil.

12 446. Prior to providing consent to inject Plaintiff with the Gardasil vaccine,  
13 Plaintiff was never informed by Merck, or anyone else, that the Gardasil clinical trials  
14 never established that Gardasil can prevent cervical or anal cancer, even though Merck  
15 in its promotional material falsely represented that Gardasil was a “cervical cancer  
16 vaccine” and that a patient who received Gardasil would result in “one less” woman or  
17 man getting cancer.

18 447. Merck’s representations were false, because in truth, Gardasil has not been  
19 proven to prevent cervical or anal cancer and is associated with a myriad of dangerous  
20 and undisclosed risks, including, but not limited to, the risk of autoimmune disease,  
21 including POTS, increased risk of developing cancer, and other serious side effects.  
22 The false representations Merck made to the patients, children, teenagers, the parents of  
23 children and teenagers, the medical community, including to Plaintiff, included:

- 24 a) that Gardasil is effective in preventing cervical and anal cancer,  
25 when Merck knew that, contrary to these representations (i) no  
26 clinical studies were performed to test whether Gardasil prevents  
27 cancer; and (ii) the clinical studies confirmed that Gardasil is indeed  
28 ineffective when used in patients who have previously been exposed

1 to HPV, and that Gardasil actually increases the risk of cervical  
2 cancer in any child or patient who has been previously exposed to  
3 HPV;

4 b) that Gardasil is safe, when in reality, Gardasil causes and presents  
5 severe risks of cancer (including cervical cancer, the very cancer it is  
6 promoted as preventing), fertility problems, autoimmune disease,  
7 including POTS, OI, and other grave illnesses;

8 c) false advertising and disease mongering by scaring parents into  
9 believing that cervical and anal cancer were far more prevalent than  
10 it really was; that Gardasil prevented cervical and anal cancer; and  
11 that Gardasil only had risks of injection site pain and fever, when in  
12 reality none of these representations were true as cervical cancer  
13 rates were declining in the United States due to Pap testing and  
14 Gardasil has not been shown to prevent cervical or anal cancer, and  
15 indeed some studies demonstrated that it actually increased the risk  
16 of cervical cancer; and Gardasil was linked to a host of serious,  
17 chronic and sometimes fatal diseases, including autoimmune  
18 diseases, as previously outlined in this Complaint.

19 448. These representations and other similar representations were made by  
20 Merck to the public, including to Plaintiff, with the intent that parents would either seek  
21 out Gardasil from their medical providers or otherwise would provide their consent  
22 when they were offered Gardasil.

23 449. At the time she provided her consent to the Gardasil injection(s), Plaintiff  
24 was not aware of the falsity of Merck's aforementioned representations concerning the  
25 safety and efficacy of Gardasil.

26 450. Plaintiff reasonably and justifiably relied upon the truth of the assurance  
27 made by Merck in its direct-to-consumer marketing concerning the efficacy and safety  
28 of Gardasil (which were also echoed by Plaintiff's medical providers), when she

1 provided consent to be injected with the Gardasil vaccine.

2 451. Had Merck's advertisements and promotional material, which Merck  
3 targeted to teenagers and the parents of teenagers, and which Plaintiff received and on  
4 which she relied, provided complete and truthful warnings and properly disclosed and  
5 disseminated the true risks, limitations and lack of efficacy associated with Gardasil,  
6 then Plaintiff's mother would not have consented to Plaintiff being injected with  
7 Gardasil.

8 452. Merck also engaged in a number of additional fraudulent activities that led  
9 to regulators, medical providers (upon information and belief, including but not limited  
10 Plaintiff's medical providers), and the general public (including directly and/or  
11 indirectly Plaintiff) to be duped into believing that Gardasil is safe and effective. These  
12 fraudulent acts are outlined in greater detail in the preceding paragraphs of this  
13 Complaint, and included, among others:

- 14 a) Failing to test Gardasil against a true inert placebo and lying to the  
15 public that Gardasil was tested against a placebo, when in reality, all,  
16 or nearly all, studies used a toxic placebo that included the dangerous  
17 aluminum adjuvant AAHS.
- 18 b) Failing to conduct a sufficient number of studies for the targeted  
19 patient population which included pre-teen girls (and boys) between  
20 the ages of nine and 12.
- 21 c) Not using the commercial dosage (and instead using a lower dosage  
22 of the adjuvant and ingredients) in one of the key clinical trials,  
23 which was used to obtain licensing for the commercial dosage of  
24 Gardasil;
- 25 d) Using very restrictive exclusionary criteria in the clinical study  
26 patient population (including for example, exclusion of anyone who  
27 had prior abnormal Pap tests, who had a history of immunological or  
28 nervous system disorders or was allergic to aluminum or other

1 ingredients), but then not revealing or warning about these  
2 exclusionary criteria in the label and knowing that for most of these  
3 ingredients and allergies, there are limited resources for the public to  
4 test for such allergies in advance of being vaccinated;

- 5 e) Failing to disclose all of the ingredients in Gardasil, including but  
6 not limited to the fact that Gardasil contains dangerous HPV L1-  
7 DNA fragments and that these DNA fragments could act as a Toll-  
8 Like Receptor 9 (TLR9) agonist – further adjuvanting the vaccine  
9 and making it more potent and dangerous.

10 453. Merck engaged in the above mentioned fraudulent conduct as well as the  
11 additional fraudulent conduct detailed throughout this Complaint with the intent to  
12 enhance Gardasil’s safety and efficacy profile and to conceal Gardasil’s serious risks  
13 and efficacy shortcomings in order to secure regulatory approval and more importantly,  
14 so as to encourage physicians and medical providers to recommend Gardasil to patients  
15 and to prepare and encourage patients to request and consent to Gardasil injections.

16 454. Plaintiff could not reasonably have discovered the falsity of Merck’s  
17 representations, the fraudulent nature of Merck’s conduct, and the defects and risks  
18 associated with Gardasil before or at the time of her injection(s). Plaintiff relied upon  
19 the skill, superior knowledge, and judgment of Merck, the manufacturer, labeler, and  
20 promoter of Gardasil, and they detrimentally relied upon Merck’s fraudulent, false, and  
21 misleading statements, omissions, and conduct.

22 455. As a proximate result of Merck’s fraudulent, false, and misleading  
23 statements, omissions, and conduct concerning the safety and efficacy of Gardasil,  
24 Plaintiff has suffered and continues to suffer severe and permanent physical injuries,  
25 and associated symptomology and has suffered severe and permanent emotional  
26 injuries, including pain and suffering. Plaintiff also has a substantial fear of suffering  
27 additional and ongoing harms, including but not limited to now being at an increased  
28 risk of cancer, and future symptoms and harms associated with her autoimmune disease

1 and other injuries caused by Gardasil.

2 456. As a direct and proximate result of her Gardasil-induced injuries, Plaintiff  
3 has suffered and continues to suffer economic losses, including considerable financial  
4 expenses for medical care and treatment, and diminished income capacity and she will  
5 continue to incur these losses and expenses in the future.

6 457. Merck's conduct, as described above, was oppressive, fraudulent, and  
7 malicious. Merck regularly risks the lives of patients, including Plaintiff, with full  
8 knowledge of the limited efficacy of Gardasil and the severe and sometimes fatal  
9 dangers of Gardasil. Merck has made conscious decisions to not warn, or inform the  
10 unsuspecting public, including Plaintiff, her mother, and her medical providers.  
11 Merck's conduct, including its false promotion of Gardasil and its failure to issue  
12 appropriate warnings concerning the severe risks of Gardasil, created a substantial risk  
13 of significant harm to children and patients who were being injected with Gardasil.

14 458. WHEREFORE, Plaintiff requests that the Court enter judgment in her  
15 favor for compensatory and punitive damages, together with interest, and costs herein  
16 incurred, and all such other and further relief as this Court deems just and proper.  
17 Plaintiff also demands a jury trial on the issues contained herein.

## 18 **COUNT SIX**

### 19 **VIOLATION OF CALIFORNIA'S UNFAIR COMPETITION LAW**

20 459. Plaintiff incorporates by reference all other paragraphs of this Complaint as  
21 if fully set forth herein, and further alleges: California's Unfair Competition Law  
22 ("UCL"), Cal. Bus. & Prof. Code §§ 17200, et seq., protects both consumers and  
23 competitors by promoting fair competition in commercial markets for goods and  
24 services. California's Unfair Competition Law is interpreted broadly and provides a  
25 cause of action for any unlawful, unfair, or fraudulent business act or practice. Any  
26 unlawful, unfair, or fraudulent business practice that causes injury to consumers falls  
27 within the ambit of California's Unfair Competition Law.

28 460. Merck engaged in substantial advertising and marketing of Gardasil within

1 the State of California.

2 461. Because of Merck's unlawful, fraudulent, and unfair business practices,  
3 Plaintiff and her mother were misled into purchasing and consenting to the Gardasil  
4 injections.

5 462. As set forth in the preceding paragraphs, Defendants has engaged in the  
6 unlawful business practice of misleading Plaintiff regarding the Gardasil vaccines' true  
7 safety. Defendants' deceptive and unlawful marketing practices have violated  
8 numerous California laws, including, inter alia: Cal. Civ. Code §§ 1709, et seq.  
9 (fraudulent deceit); Cal. Civ. Code §§ 1571, et seq. (fraud); Cal. U. Com. Code §§  
10 2313-15 (breach of express warranty); Cal. Bus. & Prof. Code §§ 17500, et seq. (false  
11 advertising and marketing); and Cal. Civ. Code §§ 1750, et seq. (violations of  
12 California's Consumer Legal Remedies Act).

13 463. Merck widely advertised and promoted Gardasil as a safe and effective  
14 vaccine that had no serious side effects.

15 464. Yet, contrary to its above referenced false claims concerning the safety and  
16 efficacy of Gardasil, Merck knew, or should have known, that Gardasil was ineffective,  
17 unreasonably dangerous and defective, and had a propensity to cause serious and life-  
18 threatening side effects, including but not limited to autoimmune diseases and other  
19 grave injuries as outlined in this Complaint.

20 465. The false, deceptive, and misleading actions, statements, and  
21 representations made by Merck, as alleged in this Complaint, are unlawful, fraudulent,  
22 and unfair business practices and acts within the meaning of the UCL. See e.g., Cal.  
23 Bus. & Prof. Code §§ 17200 et seq.

24 466. Merck's concealment of the autoimmune risks and other adverse events  
25 outlined in this Complaint was a material omission that consumers, patients, parents,  
26 and prescribing healthcare professionals should have known about prior to purchasing,  
27 consenting to injection of, or prescribing Gardasil.

28 467. Merck's concealment of the lack of efficacy and false representations

1 concerning the efficacy of Gardasil in preventing cancer was a material false  
2 representation and omission that consumers, patients, parents, and prescribing  
3 healthcare professionals should have known about prior to purchasing, consenting to  
4 injection of, or prescribing Gardasil.

5 468. Merck had sole access to material facts concerning the nature of the risks  
6 and defects associated with Gardasil as expressly stated within its promotional material  
7 and labels, and Merck knew that patients and users such as Plaintiff, her mother, and  
8 her medical providers could not have reasonably discovered the truth about the  
9 inefficacies and serious risks associated with Gardasil as alleged herein.

10 469. Plaintiff and her mother had no knowledge of the falsity or incompleteness  
11 of Merck's statements and representations concerning Gardasil.

12 470. Plaintiff's mother reasonably and justifiably relied upon the truth of the  
13 assurance made by Merck in its direct-to-consumer marketing concerning the efficacy  
14 and safety of Gardasil (which were also echoed by Plaintiff's medical providers), when  
15 she and Plaintiff provided their consent to Plaintiff being injected with the Gardasil  
16 vaccine.

17 471. Had Merck's advertisements and promotional material, which Merck  
18 targeted to teenagers and the parents of teenagers, and which Plaintiff's mother  
19 received and on which she relied, provided complete and truthful warnings and  
20 properly disclosed and disseminated the true risks, limitations, and lack of efficacy  
21 associated with Gardasil, then neither Plaintiff nor her mother would have consented to  
22 Plaintiff being injected with Gardasil.

23 472. As a direct and proximate result of Merck's unlawful, fraudulent, and  
24 unfair business practices, Plaintiff has sustained injuries and economic damages as  
25 outlined herein, including but not limited to, agreeing to being injected with Gardasil,  
26 which upon information and belief, costs more than \$100 per vial.

27 473. As a result of Merck's violation of the UCL, Plaintiff seeks an order of this  
28 Court enjoining Merck from continuing these unlawful, fraudulent, and unfair practices

1 and awarding Plaintiff remedies, including but not limited to disgorgement of Merck's  
2 profits, restitution, fees, and all other remedies available under law.

3 474. WHEREFORE, Plaintiff requests that the Court enter judgment in her  
4 favor for restitution, disgorgement of Merck's ill-gotten profits, punitive damages, and  
5 all other permissible monetary relief, together with interest, costs herein incurred,  
6 attorney fees pursuant to California Code of Civil Procedure Section 1021.5, and all  
7 such other and further relief as this Court deems just and proper. Plaintiff also requests  
8 that the Court issue an injunction prohibiting Merck from continuing its false  
9 advertising and unlawful acts and practices concerning Gardasil and to grant any other  
10 preliminary or permanent equitable relief as deemed appropriate.

11 **PRAYER FOR RELIEF**

12 WHEREFORE, Plaintiff, Catherine Boss, requests that the Court enter judgment  
13 in her favor and against Merck & Co., Inc., and Merck, Sharp and Dohme Corporation  
14 (collectively "Merck") as to all causes of action, and awarding as follows:

- 15 A. For compensatory damages, in an amount exceeding this Court's  
16 jurisdictional minimum and to be proven at trial;
- 17 B. For economic and non-economic damages in an amount to be proven at  
18 trial;
- 19 C. For medical, incidental, hospital, psychological and other expenses in an  
20 amount to be proven at trial;
- 21 D. For loss of earnings and earnings capacity, in an amount to be proven at  
22 trial;
- 23 E. For an award of pre-judgment and post-judgment interest as provided by  
24 law;
- 25 F. For exemplary and punitive damages against Merck;
- 26 G. For preliminary and/or permanent injunctive relief against Merck;
- 27 H. For an award providing for payment of reasonable fees, court costs, and  
28 other litigation expenses as permitted by law;

1 I. For such other and further relief as this Honorable Court may deem just  
2 and proper.

3 **DEMAND FOR JURY TRIAL**

4 Pursuant to Rule 38(b) of the Federal Rules of Civil Procedure, Plaintiff,  
5 Catherine Boss, hereby demands a jury trial on *all* of her claims, causes of action and  
6 issues that are triable by jury.

7 Dated: September 27, 2022

**BAUM, HEDLUND, ARISTEI, &  
8 GOLDMAN, P.C.**

9  
10 By: /s/ Bijan Esfandiari  
11 Bijan Esfandiari  
12 [besfandiari@baumhedlundlaw.com](mailto:besfandiari@baumhedlundlaw.com)  
13 10940 Wilshire Blvd., Suite 1600  
14 Los Angeles, CA 90024  
15 Telephone: (310) 207-3233  
16 Facsimile: (310) 820-7444

17 Robert F. Kennedy, Jr.  
18 (*Pro Hac Vice to be filed*)  
19 [rfk1954@gmail.com](mailto:rfk1954@gmail.com)  
20 Kennedy & Madonna, LLP  
21 48 Dewitt Mills Rd  
22 Hurley, NY, 12443  
23 Telephone: (845) 481-2622  
24 Facsimile: (845) 230-3111

25 *Attorneys for Plaintiff*